false12-312024Q30001851612NONENONENONEhttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumerationhttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration0.5P2DP10D0.67P2DP5Dhttp://fasb.org/us-gaap/2024#InvestorMember00http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrantshttp://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants00018516122024-01-012024-09-300001851612bhac:RedeemableWarrantsMember2024-01-012024-09-300001851612bhac:PublicSharesMember2024-01-012024-09-300001851612us-gaap:CommonClassAMember2024-01-012024-09-300001851612us-gaap:CommonClassAMember2024-12-110001851612us-gaap:CommonClassBMember2024-12-1100018516122023-12-3100018516122024-09-300001851612us-gaap:RelatedPartyMember2023-12-310001851612us-gaap:RelatedPartyMember2024-09-300001851612us-gaap:CommonClassAMember2024-09-300001851612us-gaap:CommonClassBMember2023-12-310001851612us-gaap:CommonClassAMember2023-12-310001851612us-gaap:CommonClassBMember2024-09-3000018516122023-01-012023-09-3000018516122023-07-012023-09-3000018516122024-07-012024-09-300001851612us-gaap:CommonClassAMember2023-01-012023-09-300001851612us-gaap:CommonClassAMember2024-07-012024-09-300001851612us-gaap:CommonClassBMember2024-07-012024-09-300001851612bhac:CommonClassANonredeemableMember2024-01-012024-09-300001851612us-gaap:CommonClassBMember2023-01-012023-09-300001851612bhac:CommonClassANonredeemableMember2023-01-012023-09-300001851612us-gaap:CommonClassAMember2023-07-012023-09-300001851612us-gaap:CommonClassBMember2024-01-012024-09-300001851612us-gaap:CommonClassBMember2023-07-012023-09-300001851612bhac:CommonClassANonredeemableMember2023-07-012023-09-300001851612bhac:CommonClassANonredeemableMember2024-07-012024-09-3000018516122024-03-310001851612us-gaap:RetainedEarningsMember2023-12-3100018516122024-06-300001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-300001851612us-gaap:RetainedEarningsMember2023-09-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-09-3000018516122023-09-300001851612us-gaap:AdditionalPaidInCapitalMember2023-09-300001851612us-gaap:AdditionalPaidInCapitalMember2024-03-310001851612us-gaap:AdditionalPaidInCapitalMember2023-12-310001851612us-gaap:PreferredStockMember2023-09-300001851612us-gaap:AdditionalPaidInCapitalMember2024-09-300001851612us-gaap:RetainedEarningsMember2024-06-300001851612us-gaap:PreferredStockMember2024-09-300001851612us-gaap:PreferredStockMember2023-12-310001851612us-gaap:PreferredStockMember2024-06-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-09-300001851612us-gaap:AdditionalPaidInCapitalMember2024-06-300001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-03-310001851612us-gaap:RetainedEarningsMember2024-03-310001851612us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-06-300001851612us-gaap:RetainedEarningsMember2024-09-300001851612us-gaap:PreferredStockMember2024-03-310001851612us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-03-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-12-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001851612us-gaap:RetainedEarningsMember2024-07-012024-09-300001851612us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-07-012024-09-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-07-012024-09-300001851612us-gaap:PreferredStockMember2024-07-012024-09-300001851612us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100018516122023-04-012023-06-300001851612us-gaap:PreferredStockMember2023-07-012023-09-300001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-04-012024-06-300001851612us-gaap:PreferredStockMember2024-04-012024-06-300001851612us-gaap:PreferredStockMember2024-01-012024-03-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-03-310001851612us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-01-012024-03-310001851612us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-04-012023-06-300001851612us-gaap:RetainedEarningsMember2023-07-012023-09-300001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-04-012024-06-300001851612us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000018516122024-01-012024-03-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-012023-09-3000018516122023-01-012023-03-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-07-012023-09-300001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-01-012023-03-310001851612us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001851612us-gaap:RetainedEarningsMember2023-01-012023-03-310001851612us-gaap:PreferredStockMember2023-01-012023-03-310001851612us-gaap:RetainedEarningsMember2024-01-012024-03-310001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-04-012023-06-300001851612us-gaap:PreferredStockMember2023-04-012023-06-300001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-01-012024-03-3100018516122024-04-012024-06-300001851612us-gaap:RetainedEarningsMember2024-04-012024-06-300001851612us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001851612us-gaap:RetainedEarningsMember2023-04-012023-06-3000018516122023-06-300001851612us-gaap:RetainedEarningsMember2023-06-300001851612us-gaap:AdditionalPaidInCapitalMember2023-03-310001851612us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-06-300001851612us-gaap:PreferredStockMember2023-06-300001851612us-gaap:AdditionalPaidInCapitalMember2023-06-300001851612us-gaap:RetainedEarningsMember2022-12-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001851612us-gaap:PreferredStockMember2022-12-310001851612us-gaap:PreferredStockMember2023-03-310001851612us-gaap:RetainedEarningsMember2023-03-3100018516122022-12-3100018516122023-03-310001851612us-gaap:AdditionalPaidInCapitalMember2022-12-310001851612us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-06-300001851612us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001851612us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-03-310001851612bhac:PolarMultiStrategyMasterFundMember2023-01-012023-09-300001851612bhac:PolarMultiStrategyMasterFundMember2024-01-012024-09-300001851612us-gaap:InvestorMember2024-01-012024-09-300001851612us-gaap:InvestorMember2023-01-012023-09-300001851612bhac:NotePayablePolarMember2024-01-012024-09-300001851612bhac:NonRedemptionAgreementsMember2024-01-012024-09-300001851612srt:MinimumMember2021-02-232021-02-230001851612us-gaap:IPOMember2021-10-042021-10-040001851612us-gaap:IPOMemberbhac:PublicWarrantsMember2021-10-040001851612us-gaap:CommonClassAMemberus-gaap:IPOMember2021-10-040001851612us-gaap:CommonClassAMemberbhac:PublicWarrantsMember2021-10-040001851612bhac:PrivatePlacementWarrantsMember2021-10-072021-10-070001851612bhac:PrivatePlacementWarrantsMember2021-10-070001851612us-gaap:IPOMember2021-10-072021-10-070001851612srt:MinimumMember2024-09-300001851612srt:MinimumMember2024-01-012024-09-300001851612us-gaap:IPOMemberus-gaap:CommonClassAMemberbhac:PublicWarrantsMember2021-10-040001851612us-gaap:IPOMemberbhac:PrivatePlacementWarrantsMember2021-10-070001851612bhac:PublicSharesMember2024-09-300001851612srt:MaximumMember2024-09-300001851612us-gaap:CommonClassAMember2024-07-310001851612us-gaap:CommonClassAMember2022-12-070001851612bhac:PurchaseAgreementMemberus-gaap:CommonClassBMemberus-gaap:InvestorMember2023-09-270001851612us-gaap:InvestorMemberbhac:PrivatePlacementWarrantsMemberbhac:PurchaseAgreementMember2023-09-270001851612bhac:PrivatePlacementWarrantsMemberbhac:PurchaseAgreementMember2023-09-270001851612bhac:PurchaseAgreementMemberus-gaap:InvestorMemberus-gaap:CommonClassBMember2023-09-272023-09-270001851612srt:MinimumMember2024-07-3100018516122023-10-062023-10-0600018516122024-07-012024-07-310001851612us-gaap:CommonClassBMember2023-10-062023-10-060001851612us-gaap:CommonClassBMember2024-07-312024-07-310001851612us-gaap:CommonClassBMemberus-gaap:InvestorMember2024-07-312024-07-310001851612us-gaap:CommonClassBMember2023-10-242023-10-240001851612us-gaap:CommonClassBMember2023-10-240001851612us-gaap:CommonClassBMember2024-07-310001851612us-gaap:CommonClassAMember2023-10-0600018516122023-10-060001851612us-gaap:CommonClassAMemberbhac:FocusImpactBH3NewcoIncMember2024-07-310001851612us-gaap:CommonClassAMember2023-10-240001851612bhac:PolarMultiStrategyMasterFundMember2023-11-030001851612bhac:PolarMultiStrategyMasterFundMember2023-11-032023-11-030001851612us-gaap:CommonClassBMember2023-12-202023-12-200001851612bhac:FocusImpactBH3NewcoIncMember2024-07-312024-07-310001851612srt:MaximumMember2024-07-312024-07-310001851612us-gaap:InvestorMemberus-gaap:CommonClassAMemberbhac:FocusImpactBH3MergerSubILLCMember2024-03-112024-03-110001851612bhac:FocusImpactBH3MergerSubILLCMemberus-gaap:InvestorMember2024-03-112024-03-110001851612bhac:FocusImpactBH3MergerSubILLCMemberus-gaap:InvestorMemberus-gaap:CommonClassAMember2024-03-110001851612bhac:XCFGlobalCapitalIncMemberbhac:FocusImpactBH3MergerSubIIIncMember2024-03-110001851612bhac:XCFGlobalCapitalIncMemberbhac:ManagementSupportAgreementMember2024-03-110001851612bhac:XCFGlobalCapitalIncMemberbhac:GLSupportAgreementMember2024-03-110001851612bhac:SponsorLetterAgreementMemberus-gaap:InvestorMembersrt:MinimumMember2024-03-110001851612bhac:FocusImpactBH3MergerSubIIIncMemberbhac:XCFGlobalCapitalIncMember2024-01-012024-09-300001851612bhac:ManagementSupportAgreementMemberbhac:XCFGlobalCapitalIncMember2024-01-012024-09-300001851612us-gaap:CommonClassAMemberus-gaap:InvestorMemberbhac:SponsorLetterAgreementMember2024-01-012024-09-300001851612bhac:GLSupportAgreementMemberbhac:XCFGlobalCapitalIncMember2024-01-012024-09-300001851612bhac:SupportAgreementsMembersrt:MinimumMember2024-03-110001851612bhac:SouleSupportAgreementMember2024-03-112024-03-110001851612bhac:SouleSupportAgreementMember2024-03-110001851612bhac:GLSupportAgreementMember2024-03-110001851612bhac:GLSupportAgreementMember2024-01-012024-09-300001851612bhac:GLSupportAgreementMember2024-03-112024-03-110001851612bhac:PromissoryNoteMember2024-01-012024-09-300001851612bhac:PromissoryNoteMember2024-09-300001851612bhac:PromissoryNoteMember2023-07-310001851612bhac:SponsorMembersrt:MaximumMemberbhac:ConvertiblePromissoryNotesMember2024-02-260001851612bhac:ConvertiblePromissoryNotesMemberbhac:SponsorMember2024-01-012024-09-300001851612bhac:XCFGlobalCapitalIncMember2024-01-012024-09-3000018516122024-08-012024-08-3000018516122023-11-0200018516122023-11-022023-11-0200018516122023-01-012023-12-310001851612us-gaap:InvestorMemberbhac:PromissoryNoteMember2024-02-260001851612bhac:PromissoryNoteMemberus-gaap:InvestorMember2023-07-3100018516122023-07-310001851612bhac:NotePayablePolarMember2023-01-012023-12-310001851612bhac:NotePayablePolarMember2024-03-120001851612bhac:NotePayablePolarMember2024-05-020001851612bhac:NotePayablePolarMember2023-11-030001851612bhac:NotePayablePolarMember2024-09-300001851612bhac:NotePayablePolarMember2024-06-300001851612bhac:NotePayablePolarMember2023-12-310001851612bhac:NotePayablePolarMember2024-03-310001851612bhac:NotePayablePolarMember2024-01-012024-03-310001851612bhac:NotePayablePolarMember2024-01-012024-06-300001851612bhac:NotePayablePolarMember2024-05-022024-05-020001851612bhac:NotePayablePolarMember2024-03-122024-03-120001851612bhac:NotePayablePolarMember2023-11-032023-11-030001851612us-gaap:IPOMemberus-gaap:CommonClassAMember2024-09-300001851612us-gaap:CommonClassAMemberus-gaap:IPOMember2024-01-012024-09-300001851612us-gaap:CommonClassBMemberus-gaap:InvestorMemberbhac:PurchaseAgreementMember2024-09-300001851612bhac:PurchaseAgreementMemberus-gaap:InvestorMemberbhac:PrivatePlacementWarrantsMember2024-09-300001851612bhac:PurchaseAgreementMember2024-09-300001851612us-gaap:CommonClassBMemberbhac:PurchaseAgreementMemberbhac:PrivatePlacementWarrantsMember2024-09-300001851612us-gaap:CommonClassBMemberbhac:PrivatePlacementWarrantsMemberbhac:PurchaseAgreementMember2024-01-012024-09-300001851612us-gaap:SubsequentEventMember2024-12-110001851612bhac:CommonClassAAndClassBMember2023-01-012023-09-300001851612bhac:CommonClassAAndClassBMember2023-07-012023-09-300001851612bhac:CommonClassAAndClassBMember2024-01-012024-09-300001851612bhac:CommonClassAAndClassBMember2024-07-012024-09-300001851612us-gaap:CommonClassAMemberus-gaap:WarrantMember2023-01-012023-09-300001851612us-gaap:WarrantMemberus-gaap:CommonClassAMember2024-01-012024-09-300001851612us-gaap:CommonClassAMember2023-09-300001851612us-gaap:IPOMemberbhac:FounderSharesMember2021-10-062021-10-060001851612bhac:FounderSharesMemberus-gaap:CommonClassBMember2021-10-072021-10-070001851612bhac:FounderSharesMember2021-10-070001851612bhac:FounderSharesMemberus-gaap:CommonClassBMember2021-10-070001851612bhac:FounderSharesMemberus-gaap:InvestorMember2021-10-060001851612bhac:FounderSharesMember2021-10-072021-10-070001851612bhac:FounderSharesMember2024-09-300001851612us-gaap:IPOMemberbhac:FounderSharesMembersrt:MaximumMember2021-10-060001851612us-gaap:InvestorMemberbhac:FounderSharesMember2021-10-062021-10-060001851612bhac:FounderSharesMember2024-01-012024-09-300001851612bhac:FounderSharesMemberus-gaap:CommonClassAMember2024-09-300001851612us-gaap:CommonClassAMemberbhac:FounderSharesMember2024-01-012024-09-300001851612srt:MinimumMemberus-gaap:CommonClassAMemberbhac:FounderSharesMember2024-09-300001851612us-gaap:CommonClassBMemberus-gaap:InvestorMember2023-11-020001851612us-gaap:InvestorMemberbhac:PrivatePlacementWarrantsMember2023-11-020001851612us-gaap:CommonClassBMemberus-gaap:InvestorMember2023-11-022023-11-020001851612us-gaap:CommonClassBMember2023-11-020001851612us-gaap:InvestorMemberus-gaap:CommonClassBMember2024-07-012024-07-310001851612us-gaap:InvestorMemberus-gaap:CommonClassBMember2023-10-312023-10-310001851612us-gaap:CommonClassAMemberbhac:PrivatePlacementWarrantsMember2021-10-070001851612us-gaap:IPOMemberus-gaap:CommonClassAMember2021-10-070001851612bhac:PrivatePlacementWarrantsMember2024-01-012024-09-300001851612bhac:ConvertiblePromissoryNotesMemberus-gaap:InvestorMember2022-11-010001851612us-gaap:InvestorMember2022-11-010001851612us-gaap:InvestorMemberbhac:ConvertiblePromissoryNotesMember2024-02-260001851612us-gaap:InvestorMember2023-01-012023-12-310001851612us-gaap:InvestorMemberbhac:AdministrativeServicesAgreementMember2021-10-072021-10-070001851612bhac:AdministrativeServicesAgreementMember2024-07-012024-09-300001851612bhac:AdministrativeServicesAgreementMember2023-01-012023-09-300001851612bhac:AdministrativeServicesAgreementMember2023-07-012023-09-300001851612bhac:AdministrativeServicesAgreementMember2024-01-012024-09-300001851612us-gaap:CommonClassBMemberus-gaap:InvestorMember2023-10-012023-10-310001851612us-gaap:CommonClassAMember2022-12-310001851612us-gaap:CommonClassAMember2023-01-012023-12-310001851612us-gaap:CommonClassAMember2024-04-012024-06-300001851612us-gaap:CommonClassAMember2024-01-012024-03-310001851612us-gaap:CommonClassAMember2024-03-310001851612us-gaap:CommonClassAMember2024-06-300001851612bhac:PrivatePlacementWarrantsMember2023-12-310001851612bhac:PublicWarrantsMember2024-09-300001851612bhac:AdditionalOfferingMemberbhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember2024-09-300001851612srt:MinimumMemberus-gaap:CommonClassAMemberbhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember2024-09-300001851612us-gaap:CommonClassAMembersrt:MinimumMemberbhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember2024-09-300001851612us-gaap:CommonClassAMemberbhac:AdditionalOfferingMembersrt:MaximumMember2024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMemberbhac:AdditionalOfferingMember2024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember2024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember2024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember2024-01-012024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember2024-01-012024-09-300001851612bhac:AdditionalOfferingMembersrt:MinimumMember2024-01-012024-09-300001851612bhac:AdditionalOfferingMember2024-01-012024-09-300001851612bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMemberbhac:AdditionalOfferingMemberus-gaap:CommonClassAMember2024-01-012024-09-300001851612us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001851612us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001851612us-gaap:FairValueMeasurementsRecurringMemberbhac:NonRedemptionAgreementsMemberus-gaap:FairValueInputsLevel3Member2024-09-300001851612us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberbhac:NotePayablePolarMember2023-12-310001851612us-gaap:FairValueMeasurementsRecurringMemberbhac:PublicWarrantsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001851612us-gaap:FairValueInputsLevel3Memberbhac:NotePayablePolarMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001851612us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberbhac:PrivatePlacementWarrantsMember2024-09-300001851612bhac:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001851612bhac:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-09-300001851612us-gaap:FairValueMeasurementsRecurringMemberbhac:EmbeddedDerivativeOnWorkingCapitalLoansMemberus-gaap:FairValueInputsLevel3Member2024-09-300001851612us-gaap:FairValueInputsLevel3Memberbhac:NonRedemptionAgreementsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001851612us-gaap:FairValueInputsLevel3Memberbhac:EmbeddedDerivativeOnWorkingCapitalLoansMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001851612bhac:PromissoryNoteMembersrt:MaximumMember2024-09-300001851612bhac:WorkingCapitalLoanConversionOptionMember2023-12-310001851612bhac:NonRedemptionAgreementsMember2023-12-310001851612bhac:WorkingCapitalLoanConversionOptionMember2024-01-012024-03-310001851612bhac:NonRedemptionAgreementsMember2024-01-012024-03-310001851612bhac:NonRedemptionAgreementsMember2024-07-012024-09-300001851612bhac:NotePayablePolarMember2024-04-012024-06-300001851612bhac:NotePayablePolarMember2024-07-012024-09-300001851612bhac:WorkingCapitalLoanConversionOptionMember2024-04-012024-06-300001851612bhac:NonRedemptionAgreementsMember2024-04-012024-06-300001851612bhac:WorkingCapitalLoanConversionOptionMember2024-07-012024-09-300001851612bhac:NonRedemptionAgreementsMember2024-03-310001851612bhac:NonRedemptionAgreementsMember2024-09-300001851612bhac:WorkingCapitalLoanConversionOptionMember2024-03-310001851612bhac:WorkingCapitalLoanConversionOptionMember2024-06-300001851612bhac:WorkingCapitalLoanConversionOptionMember2024-09-300001851612bhac:NonRedemptionAgreementsMember2024-06-300001851612bhac:NonRedemptionAgreementsMemberus-gaap:MeasurementInputExercisePriceMember2024-09-300001851612us-gaap:MeasurementInputRiskFreeInterestRateMemberbhac:NotePayablePolarMember2023-12-310001851612bhac:NotePayablePolarMemberbhac:ProbabilityOfInitialBusinessCombinationMember2024-09-300001851612bhac:NonRedemptionAgreementsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-09-300001851612us-gaap:MeasurementInputExercisePriceMemberbhac:NotePayablePolarMember2024-09-300001851612bhac:NotePayablePolarMemberus-gaap:MeasurementInputExercisePriceMember2023-12-310001851612us-gaap:MeasurementInputRiskFreeInterestRateMemberbhac:NotePayablePolarMember2024-09-300001851612bhac:ProbabilityOfInitialBusinessCombinationMemberbhac:NotePayablePolarMember2023-12-310001851612bhac:NonRedemptionAgreementsMemberbhac:ProbabilityOfInitialBusinessCombinationMember2024-09-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesbhac:Businessxbrli:purebhac:Extensionbhac:Warrantbhac:Directorbhac:Votebhac:Number

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ ~~QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~For~~ ~~the~~QUARTERLY ~~quarterly~~REPORT ~~period~~PURSUANT ~~ended~~TO ~~September~~SECTION ~~30,~~13 ~~2024~~OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

☐ ~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Focus Impact BH3 Acquisition Company

(Exact name of registrant as specified in its charter)


Delaware	001-40868	86-2249068
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)


1345 Avenue of the Americas, 33rd Floor New York, NY		10105
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 213-0243

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading Symbol:	Name of each exchange on which registered:
Units, each consisting of one share of Class A common stock and one-half of one Redeemable Warrant	BHACU	OTC Pink
Class A common stock, par value $0.0001 per share	BHAC	OTC Pink
Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50	BHACW	OTC Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~December~~May 1123, ~~2024~~2025, there were 54,~~312~~103,~~124~~489 shares of Class A common stock, par value $0.0001 per share, and 1,~~639~~608,~~916~~333 shares of Class B common stock, par value $0.0001 per share, issued and outstanding.

FOCUS IMPACT BH3 ACQUISITION COMPANY

Quarterly Report on Form

10-Q


	Table of Contents

		Page No.
PART I. FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Consolidated Condensed Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024	1
	Consolidated Condensed Statements of Operations for the three months ended March 31, 2025 and 2024 (Unaudited)	2
	Consolidated Condensed Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2025 and 2024 (Unaudited)	3
	Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (Unaudited)	4
	Notes to Consolidated Condensed Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4	Controls and Procedures	37
PART II. OTHER INFORMATION		38
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3.	Defaults Upon Senior Securities	38
Item 4.	Mine Safety Disclosures	38
Item 5.	Other Information	38
Item 6.	Exhibits	39
SIGNATURES

		Page No.
PART I. FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Consolidated Condensed Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023	1
	Consolidated Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited)	2
	Consolidated Condensed Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2024 and 2023 (Unaudited)	3
	Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (Unaudited)	4
	Notes to Consolidated Condensed Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4	Controls and Procedures	33
PART II. OTHER INFORMATION		34
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3.	Defaults Upon Senior Securities	34
Item 4.	Mine Safety Disclosures	34
Item 5.	Other Information	34
Item 6.	Exhibits	35
SIGNATURES		36

PART I—FINANCIAL INFORMATION

~~Table~~ Item ~~of Contents~~1.

~~PRT~~ Financial ~~I—FINANCIAL INFORMATION~~Statements.

Item 1. Financial Statements.

FOCUS IMPACT BH3 ACQUISITION COMPANY

CONSOLIDATED CONDENSED BALANCE SHEETS

	September 30, 2024			December 31, 2023
	March 31,2025			December 31, 2024
	(Unaudited)
ASSETS
Current assets
Cash	$	~~594~~22,~~619~~604		$	~~631~~19,~~337~~669
Tax receivable		~~20,850~~—			~~138~~24,~~277~~700
Prepaid expenses		15,~~375~~863			11,~~306~~830
Total current assets		~~616~~28,~~844~~467			~~780~~56,~~920~~199
Investments held in Trust Account		1213,~~950~~825,~~024~~381			2413,~~554~~699,~~804~~805
Total assets	$	13,~~566~~853,~~868~~848		$	2513,~~335~~756,~~724~~004
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable and accrued expenses	$	46,~~426~~180,~~109~~846		$	~~157~~4,~~789~~950,743
Excise tax payable		~~400~~416,~~854~~598			~~283~~400,~~933~~854
Income taxes payable		~~373~~207,~~845~~207			—155,221
Reserve for uncertain tax positions		—			955,617
Franchise tax payable		19,500			—
Non-Redemption Agreement		~~920~~1,240,000			—1,250,000
Derivative warrant liability		~~716~~358,000			1358,~~074,~~000
Note payable – Sponsor		110,000			—110,000
Note Payable - Polar, at fair value		~~624~~1,~~686~~066,792			~~346~~849,~~353~~839
Due to related party		27,500			6427,~~750~~500
Total current liabilities		79,~~598~~626,~~994~~443			28,~~882~~102,~~442~~157
Reserve for uncertain tax positions - long-term		115,870			—115,870
Total liabilities		79,~~714~~742,~~864~~313			28,~~882~~218,~~442~~027
Temporary equity
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 1,212,124 and 2,312,029 shares issued and outstanding at approximately $10.67 and $10.38 redemption value at September 30, 2024 and December 31, 2023, respectively		12,933,030			24,005,323
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 1,212,124 shares issued and outstanding at approximately $10.98 and $10.95 redemption value at March 31, 2025 and December 31, 2024, respectively		13,314,065			13,266,851
Stockholders’ deficit
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none outstanding		—			—
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 4,100,000 and 3,000,000 shares issued and outstanding (excluding 1,212,124 and 2,312,029 shares subject to possible redemption) at September 30, 2024 and December 31, 2023, respectively		410			300
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 4,100,000 shares issued and outstanding (excluding 1,212,124 shares subject to possible redemption) at March 31, 2025 and December 31, 2024		410			410
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 1,639,916 and 2,739,916 shares issued and outstanding at September 30, 2024 and December 31, 2023		164			274
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 1,608,333 shares issued and outstanding at March 31, 2025 and December 31, 2024		161			161
Accumulated deficit		(79,~~081~~203,~~600~~101	)		(17,~~552~~729,~~615~~445	)
Total stockholders’ deficit		(79,~~081~~202,~~026~~530	)		(17,~~552~~728,~~041~~874	)
Total liabilities, temporary equity and stockholders’ deficit	$	13,~~566~~853,~~868~~848		$	2513,~~335~~756,~~724~~004

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

FOCUS IMPACT BH3 ACQUISITION COMPANY

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended September 30,						For the nine months ended September 30,
	For the three months ended March 31,
	2024			2023			2024			2023
	2025			2024
Operating costs	$	(1,~~047~~295,~~765~~159	)	$	(~~185~~2,~~297~~646,244	)	$	~~(5,064,404~~	)	$	~~(788,932~~	)
Loss from operations		(1,~~047~~295,~~765~~159	)		(~~185~~2,~~297~~646,244	)		~~(5,064,404~~	)		~~(788,932~~	)
Other income (expense):
Other income:
Interest income		~~230~~143,~~142~~400			~~709~~320,~~811~~299			~~873,535~~			~~1,874,489~~
Change in fair value of derivative warrant liabilities		716,000			(524,470	)		358,000			1,226,150
Change in fair value of 2024 Non-redemption Agreement		10,000			—
Operating account interest income		719			—			3,374			—
Excise tax interest and penalties		(15,744	)		—
Change in fair value of NP - Polar		13,745			—			(96,577	)		—
Operating account interest income		—			1,179
Change in fair value of convertible promissory note		—			(56,185	)		—			360,789
Change in fair value of Note Payable - Polar		(216,953	)		(95,986	)
Change in fair value of Non-Redemption Agreement		(920,000	)		—			(920,000	)		—
Total other (expense) income		(79,297	)		225,492
Total other income, net		40,606			129,156			218,332			3,461,428
Loss before provision for income taxes		(1,374,456	)		(2,420,752	)
(Loss) income before provision for income taxes		(1,007,159	)		(56,141	)		(4,846,072	)		2,672,496
Provision for income taxes		(51,986	)		(84,004	)
Provision for income taxes		188			(645,032	)		(114,461	)		(889,614	)
Net loss	$	(1,426,442	)	$	(2,504,756	)
Net (loss) income	$	(1,006,971	)	$	(701,173	)	$	(4,960,533	)	$	1,782,882
Weighted average shares outstanding, Class A Common Stock subject to possible redemption		1,212,124			2,312,029
Weighted average shares outstanding, Class A Common Stock subject to possible redemption		1,570,789			5,012,592			2,063,145			5,012,592
Basic and diluted net loss per share, Class A Common Stock subject to possible redemption	$	(0.17	)	$	(0.20	)
Basic and diluted net (loss) income per share, Class A Common Stock subject to possible redemption	$	0.02		$	(0.02	)	$	(0.37	)	$	0.40
Weighted average shares outstanding, non-redeemable Class A common stock and Class B common stock		5,708,333			5,739,916
Weighted average shares outstanding, non-redeemable Class A common stock and Class B common stock		5,739,916			5,750,000			5,739,916			5,750,000
Basic and diluted net loss per share, non-redeemable Class A common stock and Class B common stock	$	(0.21	)	$	(0.36	)
Basic and diluted net loss per share, non-redeemable Class A common stock and Class B common stock	$	(0.18	)	$	(0.10	)	$	(0.73	)	$	(0.04	)

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

FOCUS IMPACT BH3 ACQUISITION COMPANY

CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~SEPTEMBER~~MARCH 3031, ~~2024~~2025

	Preferred Stock				Class A Common Stock				Class B Common Stock						Additional					Total
	Shares		Amount		Shares		Amount		Shares			Amount			Paid-In Capital		Accumulated Deficit			Stockholders’ Deficit
Balance as of December 31, 2023		—	$	—		3,000,000	$	300		2,739,916		$	274		$	—	$	(1,552,615	)	$	(1,552,041	)
Balance as of December 31, 2024		—	$			4,100,000	$	410		1,608,333		$	161		$		$	(7,729,445	)	$	(7,728,874	)
Accretion of Class A common stock to redemption value		—		—		—		—		—			—			—		(~~358~~47,~~656~~214	)		(~~358~~47,~~656~~214	)
Subscription Agreement - Polar		—		—		—		—		—			—			—		120,592			120,592
Net loss		—		—		—		—		—			—			—		(1,426,442	)		(1,426,442	)
Net loss		—		—		—		—		—			—			—		(2,504,756	)		(2,504,756	)
Balance as of March 31, 2025		—	$			4,100,000	$	410		1,608,333		$	161		$		$	(9,203,101	)	$	(9,202,530	)
Balance as of March 31, 2024		—	$	—		3,000,000	$	300		2,739,916		$	274		$	—	$	(4,295,435	)	$	(4,294,861	)
Accretion of Class A common stock to redemption value		—		—		—		—		—			—			—		(69,989	)		(69,989	)
Subscription Agreement - Polar		—		—		—		—		—			—			—		47,652			47,652
Net loss		—		—		—		—		—			—			—		(1,448,806	)		(1,448,806	)
Balance as of June 30, 2024		—	$	—		3,000,000	$	300		2,739,916		$	274		$	—	$	(5,766,578	)	$	(5,766,004	)
Conversion of Class B common stock to Class A common stock		—		—		1,100,000		110		(1,100,000	)		(110	)		—		—			—
Accretion of Class A common stock to redemption value		—		—		—		—		—			—			—		(191,130	)		(191,130	)
Excise tax payable		—		—		—		—		—			—			—		(116,921	)		(116,921	)
Net loss		—		—		—		—		—			—			—		(1,006,971	)		(1,006,971	)
Balance as of September 30, 2024		—	$	—		4,100,000	$	410		1,639,916		$	164		$	—	$	(7,081,600	)	$	(7,081,026	)

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~SEPTEMBER~~MARCH 3031, ~~2023~~2024

	~~Preferred Stock~~	Preferred Stock			~~Class A Common Stock~~	Class A Common Stock			~~Class B Common Stock~~	Class B Common Stock			~~Additional Paid-In Capital~~		~~Accumulated Deficit (1)~~			~~Total Stockholders’ Deficit (1)~~
	~~Shares~~	Shares	~~Amount~~	Amount	~~Shares~~	Shares	~~Amount~~	Amount	~~Shares~~	Shares	~~Amount~~	Amount		AdditionalPaid-In Capital		Accumulated Deficit			TotalStockholders’ Deficit
Balance as of December 31, 2022		—	$	—		—	$	—		5,750,000	$	575	$	—	$	(10,016,759	)	$	(10,016,184	)
Balance as of December 31, 2023		—	$	—		3,000,000	$	300		2,739,916	$	274	$	—		(1,552,615	)	$	(1,552,041	)
Accretion of Class A common stock to redemption value		—		—		—		—		—		—		—		(1358,~~622,652~~656	)		(1358,~~622,652~~656	)
Deemed contribution by sponsor		—		—		—		—		—		—		—		227,424			227,424
Subscription Agreement - Polar		—		—		—		—		—		—		—		120,592			120,592
Net income		—		—		—		—		—		—		—		78,752			78,752
Net loss		—		—		—		—		—		—		—		(2,504,756	)		(2,504,756	)
Balance as of March 31, 2023		—	$	—		—	$	—		5,750,000	$	575	$	—	$	(11,333,235	)	$	(11,332,660	)
Balance as of March 31, 2024		—	$	—		3,000,000	$	300		2,739,916	$	274	$	—	$	(4,295,435	)	$	(4,294,861	)
Accretion of Class A common stock to redemption value		—		—		—		—		—		—		—		(182,025	)		(182,025	)
Deemed contribution by sponsor		—		—		—		—		—		—		—		202,509			202,509
Net income		—		—		—		—		—		—		—		2,405,303			2,405,303
Balance as of June 30, 2023		—	$	—		—	$	—		5,750,000	$	575	$	—	$	(8,907,448	)	$	(8,906,873	)
Accretion of Class A common stock to redemption value		—		—		—		—		—		—		—		(415,659	)		(415,659	)
Net loss		—		—		—		—		—		—		—		(701,173	)		(701,173	)
Balance as of September 30, 2023		—	$	—		—	$	—		5,750,000	$	575	$	—	$	(10,024,280	)	$	(10,023,705	)

(1) Revised to reflect a revision to previously issued financial statements as discussed in the Company’s Form 10-K as filed with the SEC on April 23, 2024.

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

FOCUS IMPACT BH3 ACQUISITION COMPANY

CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN CASH FLOWS

(Unaudited)

	For the Nine Months Ended September 30,
	For the three months ended March 31,
	2024			2023
	2025			2024
Cash flows from operating activities
Net (loss) income	$	(4,960,533	)	$	1,782,882
Net loss	$	(1,426,442	)	$	(2,504,756	)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Interest income		(~~873~~143,~~535~~400	)		(1320,~~874,489~~299	)
Change in fair value of Non-Redemption Agreement		920,000			—
Change in fair value of 2024 Non-redemption Agreement		(10,000	)		—
Change in fair value of note payable - Polar		96,577			—
Change in fair value of Note Payable - Polar		216,953			95,986
Change in fair value of derivative warrant liability		(358,000	)		(1,226,150	)
Change in fair value of convertible promissory note		—			(360,789	)
Changes in operating assets and liabilities:
Prepaid expenses		95,~~931~~967			—4,219
Accounts payable and accrued expenses		4,268,320			132
Excise tax interest and penalties		15,744			—
Franchise taxes payable		(20,850	)		—
Accounts payable and accrued expenses		1,230,103			2,242,514
Tax receivable		(327,625	)		803,384
Delaware franchise taxes payable		44,200			9,950
Net cash used in operating activities		(1,245,715	)		(875,030	)
Income tax payable		51,986			84,004
Net cash used in operating activities		(14,889	)		(388,382	)
Cash flows from investing activities
Proceeds withdrawn from trust account for the payment of taxes		~~786~~17,~~247~~824			~~229,512~~—
Purchases of marketable securities in Trust Account		—			(104,153,634	)
Net cash provided by investing activities		17,824			—
Sale of cash and marketable securities held-to-maturity in Trust Account		—			156,663,634
Funds withdrawn for redemptions		11,692,068			—
Purchases of mutual funds in Trust Account		—			(52,860,879	)
Net cash provided by (used in) investing activities		12,478,315			(121,367	)
Cash flows from financing activities
Proceeds from convertible promissory note		—			~~988,402~~—
Proceeds from note payable - Sponsor		~~110,000~~—			—100,000
Proceeds from note payable - Polar		350,000			—
Proceeds on Stock subscription agreement		—			250,000
Repayment of promissory note to related party		~~(86,636~~—	)		(~~300~~64,~~000~~749	)
Funds withdrawn for redemptions		(11,692,068	)		—
Proceeds from promissory note to related party		—			49,386
Proceeds from promissory note to related party		49,386			350,880
Net cash provided by financing activities		—			334,637
Net cash (used in) provided by financing activities		(11,269,318	)		1,039,282
Net change in cash		2,935			(53,745	)
Net change in cash		(36,718	)		42,885
Cash at beginning of period		19,669			631,337
Cash at beginning of period		631,337			13,715
Cash at end of period	$	22,604		$	577,592
Cash at end of period	$	594,619		$	56,600
Supplemental disclosure of non-cash investing and financing activities:
Change in value of Class A common stock subject to possible redemption	$	~~619~~47,~~775~~214		$	2358,~~220,336~~656
Conversion of Class B common stock to Class A common stock	$	110		$	—
Subscription Agreement - Polar	$	—		$	120,592
Deemed contribution from Sponsor	$	—		$	429,933
Excise tax payable	$	116,921		$	—
Supplemental disclosure of cash flow information:
Income taxes paid	$	442,027		$	86,230

See accompanying notes to the unaudited consolidated condensed financial statements.

FOCUS IMPACT BH3 ACQUISITION COMPANY

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

Note 1—Organization and Plan of Business Operations

Focus Impact BH3 Acquisition Company (f/k/a/ Crixus BH3 Acquisition Company) (the “Company”) is a blank check company incorporated as a Delaware company on February 23, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (an “Initial Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

The registration statement for the initial public offering of the Company (the “Initial Public Offering”) was declared effective on October 4, 2021 and the Company consummated the Initial Public Offering by selling 23,000,000 units at a purchase price of $10.00 per Unit (“Units”) ~~per Unit~~. Each Unit consists of one Class A common stock and one-half public warrant. Each whole warrant (“Public Warrant”) entitles the holder to purchase one Class A common stock at a price of $11.50 per share.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,400,000 warrants (the “Private Placement Warrants”) at a price of $1.50 per warrant in a private placement to Crixus BH3 Sponsor LLC (the “Former Sponsor”) which is described in Note 4.

Following the closing of the Initial Public Offering, an amount of $232,300,000 or $10.10 per Unit from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (“Trust Account”) which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of an Initial Business Combination or (ii) the distribution of the Trust Account, as described below.

The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

The Company has not yet begun operations and therefore, all activity for the period from February 23, 2021 (date of inception) through ~~September~~March 3031, ~~2024~~2025, relates to the Company’s Initial Public Offering, identifying a target for the Initial Business Combination and activities necessary for the consummation of an Initial Business Combination. The Company will not generate any operating revenues until after the completion of an Initial Business Combination, at the earliest. The Company will generate non-operating income or losses in the form of interest income from the proceeds derived from the Initial Public Offering and from changes in the fair value of the warrant derivative liability, note payable – Polar, and the 2024 non-redemption agreement.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants (as defined in Note 4), although substantially all of the net proceeds are intended to be applied generally toward consummating an Initial Business Combination. The Company’s Initial Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the signing an agreement to enter into an Initial Business Combination. However, the Company will only complete an Initial Business Combination if the post-Initial Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect an Initial Business Combination.

The Company will provide the holders of Class A common stock, par value, $0.0001 per shares (“Class A common stock”, “Class A Shares” or “public shares”, and such holders, the “Public Stockholders”) with the opportunity to redeem all or a portion of their public shares upon the completion of the Initial Business Combination, either (i) in connection with a stockholder meeting called to approve the Initial Business Combination or (ii) by means of a tender offer, in either case at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the Initial Business Combination, including interest (which interest shall be net of taxes payable) divided by the number of then outstanding public shares. Notwithstanding the foregoing, if the Company seeks stockholder approval of the Initial Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the public shares. The Company will proceed with an Initial Business Combination only if it has net tangible assets of at least $5,000,001 upon consummation of the Initial Business Combination and, in the case of a stockholder vote, a majority of the outstanding Common Stock voted are voted in favor of the Initial Business Combination.

On February 27, 2025, a majority of the outstanding Common Stock voted in favor of the proposed Business Combination.

The Company will have until ~~February~~October 7, 2025 (asif ~~may~~fully be extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors) to consummate an Initial Business Combination (the “Combination Period”). If the Company has not completed an Initial Business Combination by the such date, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares, which redemption will completely extinguish the rights of the Public Stockholders as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its Board of Directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In the event of a liquidation, the Public Stockholders will be entitled to receive a full pro rata interest in the Trust Account (initially $10.10 per share, plus any pro rata interest earned on the Trust Fund not previously released to the Company to pay its tax obligations and less up to $100,000 of interest to pay dissolution expenses). There will be no redemption rights or liquidating distributions with respect to the founder shares (as defined below) or the Private Placement Warrants, which will expire worthless if the Company fails to complete an Initial Business Combination on or before ~~February~~the 7,end ~~2025~~of ~~(as~~the ~~may~~Combination ~~be extended until April 7, 2025)~~Period.

Charter Amendments and Early Redemptions; Purchase Agreement; Anchor Transfer Agreements

On December 7, 2022, following approval by the Company’s stockholders at a special meeting (the “December 2022 Special Meeting”), the Company effected a charter amendment and an amendment to its Investment Management Trust Agreement with Continental Stock Transfer & Trust Company, the effect of which was to change the Company’s prior termination date from April 7, 2023 to August 7, 2023 (and further extended to October 6, 2023 by the Former Sponsor providing the Company with the requisite notice and the deposit amount). In connection with the December 2022 Special Meeting, 17,987,408 public shares were tendered for redemption (the “First Redemption”). Immediately after giving effect to the First Redemption, the Company had approximately $51.2 million remaining in the Trust Account.

On September 27, 2023, the Company, the Former Sponsor and Focus Impact BHAC Sponsor, LLC (the “Sponsor”) entered into a Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, subject to satisfaction of certain conditions, the Sponsor (i) agreed to purchase an aggregate of 3,746,303 shares of Class B common stock (as defined below) from the Former Sponsor and each of the anchor investors and 4,160,000 Private Placement Warrants from the Former Sponsor for an aggregate purchase price of $16,288 and (ii) became the Sponsor of the Company (together, the “Purchase”). In connection therewith, the Former Sponsor also entered into anchor transfer agreements with each of its anchor investors, whereby each anchor investor agreed, subject to the conditions contained therein, when and as directed by the Former Sponsor, to transfer 2/3 of their shares of Class B common stock for no consideration; provided, however, upon the request of an anchor investor, the Former Sponsor shall pay to them $0.0043 per share.

The Purchase Agreement closed as of November 2, 2023. In connection with the closing of the Purchase, the Sponsor, among other things, joined as a party to (i) the Letter Agreement, dated October 4, 2021, by and between the Company and the Former Sponsor and (ii) the Registration and Stockholder Rights Agreement, dated October 4, 2021, among the Company, the Former Sponsor and certain security holders party thereto. On November 3, 2023, the Company changed its corporate name to “Focus Impact BH3 Acquisition Company”, pursuant to an amendment to its amended and restated certificate of incorporation filed with the Delaware Secretary of State on November 3, 2023.

On October 6, 2023, following approval by our stockholders at a special meeting (the “October 2023 Special Meeting”), the Company effected an amendment to its amended and restated certificate of incorporation, the effect of which was to (i) further extend the period of time by which the Company has to consummate an Initial Business Combination to July 31, 2024 and (ii) provide for the right of a holder of shares of Class B common stock to convert such shares into shares of Class A common stock on a one-to-one basis at any time and from time to time at the election of the holder. In connection with the October 2023 Special Meeting, 2,700,563 public shares were tendered for redemption (the “Second Redemption”) and the Former Sponsor converted 3,000,000 of its shares of Class B common stock into shares of Class A common stock (the “Conversion”). Upon conversion of Class B common stock to Class A common stock, such Class A common stock will not be entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions. Immediately after giving effect to the Second Redemption and the Conversion, on October 24, 2023, the Company had approximately $24.3 million remaining in the Trust Account, and 5,312,029 shares of Class A common stock (including the 3,000,000 converted shares of Class B common stock) and 2,750,000 shares of Class B Common Stock outstanding.

In connection with the October 2023 Special Meeting, the Company, the Former Sponsor and the Sponsor entered into non-redemption agreements on substantially the same terms with certain stockholders of the Company, pursuant to which such stockholders agreed not to redeem (or to validly rescind any redemption requests on) an aggregate of 1,946,794 shares of Class A common stock (the “Non-Redeemed Shares”) in connection with the October 2023 Special Meeting. In exchange for the foregoing commitments not to redeem such Non-Redeemed Stock, the Sponsor agreed to transfer an aggregate of 389,359 shares of common stock held by the Sponsor to such stockholders immediately following consummation of an Initial Business Combination.

On November 3, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with the Sponsor and Polar Multi-Strategy Master Fund (“Polar”), an unaffiliated third party, pursuant to which Polar agreed to make capital contributions of up to $1,200,000 (the “Capital Contribution”) from time to time, at the request of the Company, subject to the terms and conditions of the Subscription Agreement, to the Company. Pursuant to the Subscription Agreement, the Capital Contribution shall be repaid to Polar by the Company within five (5) business days of the Company closing an ~~initial~~Initial Business Combination. Polar may elect to receive such repayment (i) in cash or (ii) in shares of common stock of the surviving entity in such Initial Business Combination (the “Surviving Entity”) at a rate of one share of common stock for each ten dollars ($10.00) of the Capital Contribution that is funded. Additionally, in consideration of the Capital Contribution, at the closing of an Initial Business Combination, the Surviving Entity will issue to Polar one share of common stock for each dollar of Capital Contribution that is funded prior to the closing.

On December 20, 2023, one of the Company’s anchor investors submitted 10,084 Class B common stock to the Company for no consideration to be cancelled.

On July 31, 2024, following approval by our stockholders at a special meeting (the “July 2024 Special Meeting”), the Company effected an amendment to its amended and restated certificate of incorporation, the effect of which was to (i) further extend the period of time by which the Company has to consummate an Initial Business Combination (the “Termination Date”) to February 7, 2025 and to allow the Company, without the need for another stockholder vote, to elect to extend the Termination Date on a monthly basis for up to two times, by an additional one month each time, after February 7, 2025, by resolution of the Company’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date and (ii) eliminate the limitation that the Company may not redeem public stock to the extent that such redemption would result in the Company having net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended), of less than $5,000,001 in order to allow the Company to redeem the Public Stock irrespective of whether such redemption would exceed the Redemption Limitation.

In connection with the July 2024 Special Meeting, the holders of 1,099,905 shares of Class A common stock properly exercised their right to redeem their shares (the “Third Redemption”) for cash at a redemption price of approximately $10.63 per share, for an aggregate redemption amount of $11,692,068. In addition, in connection with the July 2024 Special Meeting, the Sponsor and Former Sponsor converted an aggregate of 1,100,000 of their shares of Class B common stock into shares of Class A common stock on a one for one basis. Such converted shares of Class A common stock are not entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions. After giving effect to the Third Redemption and the conversion, the Company had approximately $12.9 million remaining in the Trust Account, 5,312,124 shares of Class A common stock (including 4,100,000 converted shares of Class B common stock) and 1,639,916 shares of Class B common stock outstanding.

In connection with the July 2024 Special Meeting, the Company and NewCo (as defined below) entered into non-redemption agreements (“2024 Non-Redemption Agreements”) with certain stockholders of the Company pursuant to which, such stockholders agreed not to redeem (or to validly rescind any redemption requests on) an aggregate of 1,047,399 shares of Class A common stock in connection with the July 2024 Special Meeting and to hold such shares through the July 2024 Special Meeting. In exchange for the foregoing commitments not to redeem such shares of Class A common stock, NewCo agreed to issue to such stockholders, for no additional consideration, an aggregate of 174,566 shares of Class A common stock of NewCo (and up to an aggregate of 232,750 shares of Class A common stock of NewCo if the Company utilizes the two monthly extensions described above), in connection with the consummation of the Initial Business Combination.

On December 17, 2024, one of the Company’s anchor investors submitted 31,583 Class B common stock to the Company for no consideration to be cancelled. After giving effect to the forfeiture of shares, we had 5,312,124 shares of Class A common stock (including 4,100,000 converted shares of Class B common stock) and 1,608,333 shares of Class B common stock outstanding.

Additionally, the Company has utilized the two monthly extensions described above and extended the Combination Period to April 7, 2025. As a result, in connection with the consummation of the Business Combination, an aggregate of 232,750 shares of NewCo Common Stock will be issued to stockholders that entered into the 2024 Non-Redemption Agreements.

On March 21, 2025, the Company filed a definitive proxy statement in connection with a special meeting to be held on April 7, 2025 in order to extend its termination date to a new termination date of May 7, 2025 (as may be extended by the Company’s board of directors until October 7, 2025) (the “2025 Extension”).

On April 7, 2025, the Company held a special meeting of stockholders (the “April 2025 Special Meeting”) to amend the Company’s amended and restated certificate of incorporation, as amended, to (i) extend the Termination Date from April 7, 2025 to May 7, 2025 (the “Charter Extension Date”), and to allow the Company, without the need for another stockholder vote, to elect to extend the Termination Date on a monthly basis for up to five times, by an additional one month each time, after the Charter Extension Date, by resolution of the Company’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date (such amendment, the “April 2025 Extension Amendment” and such proposal, the “April 2025 Extension Amendment Proposal”). The stockholders of the Company approved the April 2025 Extension Amendment Proposal at the April 2025 Special Meeting. Following the April 2025 Special Meeting, the Company's board of directors has resolved to extend the Charter Extension Date until June 7, 2025.

In connection with the vote to approve the April 2025 Extension Amendment Proposal and the vote to approve the Business Combination (as described below), the holders of an aggregate of 1,208,635 shares of Class A common stock exercised their right to redeem their shares for cash at a redemption price of approximately $10.83 per share, for an aggregate redemption amount of approximately $13,094,093.

After giving effect to the redemptions, the Company has 4,103,489 shares of Class A common stock, of which 3,489 shares of Class A common stock are held by public shareholders, and 1,608,333 shares of Class B Common Stock outstanding.

Proposed Business Combination

On March 11, 2024, the Company entered into a business combination agreement (the “Business Combination Agreement”) with Focus Impact BH3 Newco, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“NewCo”), Focus Impact BH3 Merger Sub I1, LLC, a Delaware limited liability company and wholly owned subsidiary of NewCo (“Merger Sub 1”), Focus Impact BH3 Merger Sub II2, Inc., a Delaware corporation and wholly owned subsidiary of NewCo (“Merger Sub 2”), and XCF Global Capital, Inc., a Nevada corporation (“XCF”). Pursuant to the Business Combination Agreement, and subject to the terms and conditions contained therein, the business combination will be effected in two steps: (a) the Company will merge with and into Merger Sub 1 (the “NewCo Merger”), with Merger Sub 1 being the surviving entity of the NewCo Merger as a wholly owned subsidiary of NewCo; and (b) immediately following the NewCo Merger, Merger Sub 2 will merge with and into XCF (the “Company Merger” and, together with the NewCo Merger and all other transactions contemplated by the Business Combination Agreement, the “Business Combination”), with XCF being the surviving corporation of the Company Merger as a wholly owned subsidiary of NewCo. As a result of the Business Combination, NewCo will become a new publicly-traded company.

On February 5, 2025, the Securities and Exchange Commission declared effective the registration statement on Form S-4, initially publicly filed by NewCo and XCF with the SEC on July 31, 2024. On February 27, 2025, the Company’s stockholder approved at a special meeting the Business Combination Agreement and the transactions contemplated thereby. We expect to close the XCF Business Combination in the first half of 2025.

The Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, the following transactions will occur:

(i) the Company will merge with and into Merger Sub 1, with Merger Sub 1 being the surviving entity of the NewCo Merger as a direct wholly owned subsidiary of NewCo, and (x) each share of Class A common stock outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one share of NewCo’s Class A common stock, par value $0.0001 per share (“NewCo Common Stock”), (y) each share of Class B common stock, outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one share of NewCo Common Stock, and (z) each warrant of the Company outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one warrant of NewCo (the “NewCo Warrants”), with NewCo assuming the Company’s rights and obligations under the existing warrant agreement; and

(ii) immediately following the NewCo Merger, Merger Sub 2 will merge with and into XCF, with XCF being the surviving corporation of the Company Merger as a direct wholly owned subsidiary of NewCo, and each share of common stock of XCF outstanding immediately prior to the effectiveness of the Company Merger will be converted into the right to receive shares of NewCo Common Stock determined in accordance with the Business Combination Agreement based on a pre-money equity value of XCF of $1,750,000,000, subject to adjustments for net debt and transaction expenses, and a price of $10.00 per share of NewCo Common Stock.

Conditions to Closing

The Business Combination Agreement is subject to the satisfaction or waiver of certain customary closing conditions, including, among others, (a) approval of the Business Combination and related agreements and transactions by the Company’s stockholders and the XCF stockholders, (b) effectiveness of the proxy / registration statement on Form S-4 (the “Registration Statement”) to be filed by the Company and NewCo in connection with the Business Combination, (c) expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, (d) receipt of approval for listing on the New York Stock Exchange (“NYSE”) or The Nasdaq Stock Market LLC (“Nasdaq”), as applicable, the shares of NewCo Common Stock to be issued in connection with the Business Combination, and (e) the absence of any order, law or other legal restraint or prohibition preventing the consummation of the Business Combination in effect. Other conditions to XCF’s obligations to consummate the Business Combination include, among others, (i) the accuracy of the representations and warranties of the Company as of the closing of the Business Combination (the “Closing”), (ii) the performance or compliance of each of the Company’s covenant in all material respects at or prior to the Closing and (iii) receipt of a certificate signed by an authorized officer of the Company certifying the satisfaction of the preceding clauses (i) and (ii). Other conditions to the Company’s obligations to consummate the Business Combination include, among others, (v) closing of the acquisition of New Rise Renewables, LLC and New Rise SAF Renewables Limited Liability Company (collectively, “New Rise”), (w) entry into an amended and restated supply and offtake agreement with a key supplier or another party (the “Key Agreement”) on terms and conditions reasonably satisfactory to the Company, (x) the accuracy of the representations and warranties of XCF as of the Closing, (y) the performance or compliance of each XCF covenant in all material respects at or prior to the Closing and (z) receipt of a certificate signed by an XCF authorized officer certifying the satisfaction of the preceding clauses (x) and (y).

Covenants

The Business Combination Agreement contains covenants, including, among others, providing for (i) XCF to conduct its business in the ordinary course in all material respects through the Closing, (ii) the parties to not initiate any negotiations or enter into any agreements for certain alternative transactions, (iii) XCF to prepare and deliver to the Company certain audited and unaudited consolidated financial statements of XCF, (iv) the Company and NewCo to prepare, with the assistance of XCF, and the Company and NewCo to file, the Registration Statement and take certain other actions to obtain the requisite approval of the Company’s stockholders of certain proposals regarding the Business Combination, and (v) the parties to use reasonable best efforts to obtain necessary approvals from governmental agencies.

Representations and Warranties

The Business Combination Agreement contains customary representations and warranties by the Company and XCF for transactions of this type regarding themselves and their respective businesses. The representations and warranties of the respective parties to the Business Combination Agreement will not survive the Closing of the Business Combination.

Termination

The Business Combination Agreement contains certain termination rights for both the Company and XCF including, among others, that the Business Combination Agreement may be terminated at any time prior to the Closing (i) by mutual written consent of the Company and XCF, (ii) by written notice from either the Company or XCF to the other if certain approvals of the Company’s stockholders, to the extent required under the Business Combination Agreement, are not obtained as set forth therein, (iii) by written notice from the Company, if certain approvals of the XCF stockholders are not obtained within two (2) business days after the Registration Statement is declared effective, (iv) by written notice from the Company if the Key Agreement is not entered into by a specified date or a key supplier exercises certain rights under the Key Agreement in connection with the Business Combination and (v) by either the Company or XCF in certain other circumstances set forth in the Business Combination Agreement, including, among others, (a) if the Closing is permanently enjoined, restrained or prohibited by the terms of a final, non-appealable governmental order, (b) in the event of certain uncured breaches by the other party, (c) if the Company’s stockholders do not approve the Business Combination or (d) if the Closing has not occurred on or prior to September 11, 2024 (the “Business Combination Termination Date”), provided that the Business Combination Termination Date will be automatically extended to November 11, 2024 if the Registration Statement is not declared effective on or prior to September 11, 2024.

On November 29, 2024, the Business Combination Agreement was amended to extend the Business Combination Termination Date to March 31, 2025, and on April 4, 2025, the Business Combination Termination Date was amended and extended to May 31, 2025.

Table of Contents

Reimbursable Expenses

Pursuant to the Business Combination Agreement, XCF has agreed to pay for or reimburse, as the case may be, the Company for all expenses due and payable by the Company in connection with the Business Combination (such expenses, collectively, “Reimbursable Expenses”). Such Reimbursable Expenses include:

1) any expenses payable to any governmental authority in connection with the Business Combination Agreement, including the Hart-Scott-Rodino Act filing fee and the S-4 filing fee;

2) registrar, transfer agent and printer expenses;

3) fees and expenses of third party advisors;

4) fees and expenses of auditors and accountants;

5) excise taxes of the Company; and

6) any placement fee and any other fees, costs or expenses incurred in connection with NewCo’s listing on the Applicable Exchange.

In the event that any Reimbursable Expenses become due and payable prior to the Closing, XCF has agreed to pay such Reimbursable Expenses directly on behalf of the Company, within five (5) business days of its receipt of a written statement setting forth the amount of such Reimbursable Expenses from the Company. Additionally, XCF has agreed to pay any Reimbursable Expenses which are outstanding, or which will become due and payable, as of a termination of the Business Combination Agreement.

Amendment No. 1 to the Business Combination Agreement

On November 29, 2024, the Company, NewCo, Merger Sub 1, Merger Sub 2 and XCF entered into Amendment No. 1 to the Business Combination Agreement, which amended the Business Combination Agreement to extend the Business Combination Termination Date to March 31, 2025.

Amendment No. 2 to the Business Combination Agreement

On April 4, 2025, the Company, NewCo, Merger Sub 1, Merger Sub 2 and XCF entered into Amendment No. 2 to the Business Combination Agreement, which amended the Business Combination Agreement to extend the Business Combination Termination Date to May 31, 2025.

Certain Related Agreements

Sponsor Letter Agreement

On March 11, 2024, concurrently with the execution and delivery of the Business Combination Agreement, the Company entered into a Sponsor Letter Agreement (the “Sponsor Letter Agreement”), with the Sponsor and NewCo, pursuant to which the Sponsor has unconditionally and irrevocably agreed to, among other things: (a) vote at any meeting of the stockholders of the Company, and in any action by written resolution of the stockholders of the Company, all of the shares of Class B common stock held by the Sponsor to approve the Business Combination and all related transactions and proposals; (b) vote against any proposal, action or agreement that would result in a breach of any of the Company’s covenants, representations, warranties or other obligations or agreements under the Business Combination Agreement; and (c) waive any rights to adjustment or other anti-dilution or similar protections with respect to the rate at which the shares of Class B common stock held by the Sponsor will convert into other shares of capital stock of the Company or shares of NewCo Common Stock in connection with the Business Combination and related transactions; in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement.

Pursuant to the Sponsor Letter Agreement, the Sponsor also agreed to, among other things, certain lock-up restrictions with respect to the shares of NewCo Common Stock until the earlier of (i) 12 months following the Closing and (y) the date on which NewCo completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of NewCo’s stockholders having the right to exchange their equity for cash, securities or other property, subject to certain exceptions; provided that such lock-up restrictions will lapse prior to their expiration upon the occurrence of certain events, including the closing price of the shares of NewCo Common Stock equaling or exceeding $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing at least 150 days after the Closing.

On February 20, 2025, the Company agreed to waive the lock-up restrictions and, as a result, none of the shares of the NewCo Common Stock that will be outstanding upon the completion of the Business Combination will be subject to any contractual restrictions on transfer of those shares.

Support Agreements

On March 11, 2024, concurrently with the execution and delivery of the Business Combination Agreement, the Company, NewCo and XCF entered into Company Support Agreements (collectively, the “Support Agreements”) with (i) Randy Soule, majority stakeholder of New Rise, and his affiliated entity (the “Soule Support Agreement”), (ii) GL Part SPV I, LLC, an existing XCF stockholder and New Rise equityholder (the “GL Support Agreement”), (iii) certain XCF stockholders (the “Company Support Agreement”) and (iv) certain members of XCF management (the “Management Support Agreement”). Pursuant to the Support Agreements, certain XCF stockholders and New Rise equityholders agreed to, among other things, vote to adopt and approve the Business Combination Agreement and all other documents and transactions contemplated thereby, in each case, subject to the terms and conditions of the Support Agreements, and vote against any alternative transaction, business combination or agreement that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, adversely affect or prevent the Closing of the Business Combination or the Support Agreements or result in a breach of any covenant, representation, warranty or any other obligation or agreement thereunder.

Pursuant to the Support Agreements, certain XCF and New Rise stockholders also agreed to, among other things, (a) to the extent required or applicable, vote or provide consent for purposes of authorizing and approving the Business Combination or the Business Combination Agreement, (b) when any meeting of XCF stockholders is held, appear at such meeting or otherwise cause the XCF stockholder’s Covered Shares (as defined in the applicable Support Agreements) to be counted as present thereat for purposes of calculating a quorum, or respond to the request by XCF for written consent, as applicable, (c) vote or provide consent in any other circumstances upon which a consent or other approval is required under XCF’s organizational documents (as applicable) and (d) not transfer any Covered Shares through the Closing. Notwithstanding the foregoing, the Soule Support Agreement and the GL Support Agreement provide that unless and until XCF or the Company obtains not less than $50 million in additional financing following the execution and delivery of the Business Combination Agreement, such parties may transfer any direct or indirect equity interests in New Rise in an aggregate amount of up to the lesser of (x) 15% of such parties’ equity interests in New Rise and (y) $100 million, in the case of Randy Soule and his affiliated entity, or $50 million, in the case of GL Part SPV I, LLC.

Pursuant to the Support Agreements:

(i) the members of XCF management party to the Management Support Agreements have also agreed that they will not transfer shares of NewCo Common Stock held by such parties until the earlier of (x) twelve months after the Closing and (y) the date on which NewCo (or its successor) completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of NewCo’s (or such successor’s) stockholders having the right to exchange their securities for cash, securities or other property; provided that such transfer restrictions will lapse prior to their expiration upon the occurrence of certain events, including the closing price of the shares of NewCo Common Stock equaling or exceeding $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing at least 150 days after the Closing;

Pursuant to the Support Agreements:

(ii) each of the XCF stockholders party to the Company Support Agreements and the party to the GL Support Agreement have also agreed that with respect to 90% of shares of NewCo Common Stock held by such parties (the “Lock-up Shares”), they will not transfer such Lock-up Shares until the earlier of (x) twelve months after the Closing and (y) the date on which NewCo (or its successor) completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of NewCo’s (or such successor’s) stockholders having the right to exchange their securities for cash, securities or other property; provided that such transfer restrictions will lapse prior to their expiration upon the occurrence of certain events, including the closing price of the shares of NewCo Common Stock equaling or exceeding $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing at least 150 days after the Closing; provided, further, that such parties may transfer (A) on or after 90 days following the first quarterly earnings release published following the Closing, 10% of the Lock-up Shares, (B) on or after 180 days following the closing date of the Business Combination, 30% of the Lock-up Shares and (C) on or after 360 days following the closing date of the Business Combination, 60% of the Lock-up Shares; and

(iii) the Soule Support Agreement does not contain any lock-up restrictions following the Closing.

11 On February 20, 2025, the Company agreed to waive the lock-up restrictions and, as a result, none of the shares of the NewCo Common Stock that will be outstanding upon the completion of the Business Combination will be subject to any contractual restrictions on transfer of those shares.

Table of Contents

Securities Listing

On October 7, 2024, the Company received a notice (the “Delisting Notice”) from the staff of the Listing Qualifications Department of Nasdaq stating that Nasdaq has determined to delist the Company’s securities from The Nasdaq Capital Market and will suspend trading in those securities effective at the open of business on October 14, 2024. Nasdaq reached its decision pursuant to Nasdaq IM-5101-2 because the Company did not complete one or more business combinations within 36 months of the effectiveness of its Initial Public Offering registration statement.

Following the suspension of trading on Nasdaq, the Company’s Units, shares of Class A common stock and redeemable warrants trade on the OTC Pink Marketplace under the symbols “BHACU,” “BHAC” and “BHACW,” respectively. The Company remains subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended.

Going Concern

The Company has incurred and expects to continue to incur additional costs in pursuit of its Initial Business Combination. The Company has determined that it will not be able to sustain operations for the next twelve months without additional financing. As of ~~September~~March 3031, ~~2024~~2025, the Company had $~~594~~22,~~619~~ 604 in its operating bank account available for working capital needs, $1213,~~950~~825,~~024~~381 investments in liquid securities held in its Trust Account, which are not available for working capital needs, and a working capital deficit of $69,~~982~~597,~~150~~976.

Until the consummation of the Initial Public Offering, the Company’s liquidity needs were satisfied through a payment of $25,000 from the Former Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the founder shares (as defined in Note 3) and a Note Payable to Former Sponsor (Note 3) in the amount of $563,009 that was fully repaid on October 7, 2021.

The Company had net borrowings of $988,402 pursuant to the Convertible Promissory Note issued to the Former Sponsor (Note 5) and on July 31, 2023, the Company issued a non-interest-bearing promissory note in the aggregate principal amount of up to $1,052,644 to the Former Sponsor (the “Extension Promissory Note”). At the closing of the Purchase Agreement with the Sponsor on November 2, 2023, the Convertible Promissory Note and Extension Promissory Note were terminated and of no further force and effect, resulting in loan forgiveness by the note holder.

In association with the Subscription Agreement (discussed in Note 3), the Company has borrowed $1,200,000.

On February 26, 2024, the Company issued an unsecured promissory note in the total principal amount of up to $500,000 (the “FI Sponsor Promissory Note”) to the Sponsor and had borrowed $110,000 under the FI Sponsor Promissory Note at ~~September~~March 3031, ~~2024~~2025.

XCF has agreed to pay certain costs on behalf of the Company. Since entering into the Business Combination Agreement and as of ~~September~~March 3031, 2025 and December 31, 2024, XCF has paid $~~217~~517,~~232~~487 and $353,505, respectively, to or on behalf of the Company.

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution, should the Company be unable to complete an Initial Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern. The Company has until February 7, 2025 (as may be extended until April 7, 2025), to consummate an Initial Business Combination. It is uncertain that the Company will be able to consummate an Initial Business Combination by this time. If an Initial Business Combination is not consummated by this date, and the Termination Date is not extended beyond April 7, 2025, there will be a mandatory liquidation and subsequent dissolution. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 7, 2025 (as may be extended until April 7, 2025). 11

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that its inability to satisfy its working capital obligations as of the expected mandatory liquidation date and subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. The Company has until October 7, 2025 (as extended by the board of directors), to consummate an Initial Business Combination, which would provide the Company with the ability to satisfy its working capital obligations. However, it is uncertain that the Company will be able to consummate an Initial Business Combination by this time. If an Initial Business Combination is not consummated by this date, and the Termination Date is not extended beyond October 7, 2025, there will be a mandatory liquidation and subsequent dissolution. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after October 7, 2025.

As a plan to alleviate its going concern, on March 11, 2024, the Company entered into a proposed Business Combination Agreement with XCF.

Note 2—Significant Accounting Policies

Basis of Presentation

The Company’s unaudited consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited consolidated condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the Company’s Annual Report on ~~Form10~~Form 10-K for the period ended December 31, ~~2023~~2024, as filed with the SEC on ~~April~~March 2326, ~~2024~~2025, which contains the audited financial statements and notes thereto. The interim results for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~2025 are not necessarily indicative of the results to be expected for the year ending December 31, ~~2024~~2025 or for any future interim periods.

The consolidated condensed statement of changes in stockholders’ deficit for December 31, 2022, March 31, 2023 and June 30, 2023 has been revised to reflect a revision to previously issued financial statements as discussed in the Company’s Form 10-K as filed with the SEC on April 23, 2024.

Table of Contents

Principles of Consolidation

The accompanying ~~unaudited~~ condensed consolidated financial statements include the accounts of the Company, ~~and~~ its wholly-owned subsidiary, Focus Impact BH3 Newco, Inc., and Focus Impact BH3 Newco, Inc.’s wholly-owned ~~NewCo~~subsidiaries, Focus Impact BH3 Merger Sub 1, LLC and Focus Impact BH3 Merger Sub 2, Inc. All intercompany transactions have been eliminated.

Segment Reporting

The Company complies with ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements. The Company adopted ASU 2023-07 on January 1, 2024. The amendments were applied retrospectively to all prior periods presented in the condensed consolidated financial statements (see Note 8).

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities and Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

1312

Use of Estimates

The preparation of these ~~unaudited~~condensed consolidated ~~condensed~~ financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the ~~unaudited~~condensed consolidated ~~condensed~~ financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the ~~unaudited~~condensed consolidated ~~condensed~~ financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these ~~unaudited~~condensed consolidated ~~condensed~~ financial statements is the determination of the fair value of the Company’s financial instruments. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

As of ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, the Company had $~~594~~22,~~619~~ 604 and $~~631~~19,~~337~~669, respectively, in cash outside of the Trust Account available for working capital needs. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.

In August 2024 the Company withdrew $677,784 from the Trust Account for the payment of taxes. As of September 30, 2024 $40,000 of taxes have been paid from those funds.

Investments Held in Trust Account

As of ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, investments held in Trust Account consisted of mutual funds that invest primarily in U.S. government securities and generally have a readily determinable fair value. Such securities and investments in mutual funds are classified as available-for-sale and presented on the balance sheets at fair value at the end of the reporting period. Interest, dividends, gains and losses resulting from the change in fair value of these securities are included in income from investments held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts or investment accounts in a financial institution, which at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. Additionally, the Company has a receivable from XCF for the payment of operating costs and excise taxes of the Company. As there is uncertainty with the Company’s ability to collect this receivable, the Company has recognized a reserve for the full amount of the receivable.

Stock Based Compensation

The Company complies with ASC 718 Compensation — Stock Compensation regarding Founder Shares acquired by directors of the Company. The acquired shares shall vest upon the Company consummating an Initial Business Combination (the “Vesting Date”). If prior to the Vesting Date, the director or officer is removed from office or ceases to be a director or officer, the Company will have the right to repurchase the individual’s founder shares at the price paid by the individual. Holders of the Company’s founder shares have agreed not to transfer, assign or sell any of their founder shares and any shares of our Class A common stock issuable upon conversion thereof until the earlier to occur of: (i) one year after the completion of our Initial Business Combination; and (ii) subsequent to the Initial Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our Initial Business Combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of the public stockholders having the right to exchange their shares of common stock for cash, securities or other property (except to certain permitted transferees and under certain limited circumstances). Any permitted transferees will be subject to the same restrictions and other agreements of our initial stockholders with respect to any founder shares (except that the anchor investors will be permitted to abstain from voting founder shares).

The shares were issued on November 2, 2023, and the shares vest, not upon a fixed date, but upon consummation of an Initial Business Combination. Since the approach in ASC 718 is to determine the fair value without regard to the vesting date, the Company has determined the valuation of the Class B shares as of November 2, 2023. The valuation resulted in a fair value of $3.13 per share as of November 2, 2023, or an aggregate of $156,500 for the 50,000 shares. The aggregate amount paid for the transferred shares was approximately $200. The excess fair value over the amount paid is $156,300, which is the amount of share-based compensation expense which the Company will recognize upon consummation of an Initial Business Combination.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement” (“Topic 820”), approximates the carrying amounts represented in the accompanying financial statements. The carrying amounts of working capital balances approximate their fair values due to the short maturities of these items. Topic 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of characteristics specific to the financial instruments, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

Financial instruments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value. The three levels of the fair value hierarchy under Topic 820 are as follows:

Level 1—Unadjusted quoted prices in active markets for identical financial instruments at the measurement date are used.

Level 2—Pricing inputs are other than quoted prices included within Level 1 that are observable for the investment, either directly or indirectly. Level 2 pricing inputs include quoted prices for similar financial instruments in active markets, quoted prices for identical or similar financial instruments in markets that are not active, inputs other than quoted prices that are observable for the financial instruments and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Table of Contents

Level 3—Pricing inputs are unobservable and include situations where there is little, if any, market activity for the financial instruments. The inputs used in determination of fair value require significant judgment and estimation.

In some cases, the inputs used to measure fair value might fall within different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the financial instrument is categorized in its entirety is determined based on the lowest level input that is significant to the financial instrument.

The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items.

Convertible Promissory Notes

The Company ~~accounts~~accounted for its Convertible Promissory Note under ASC 815 “Derivatives and Hedging” (“ASC 815”). Under 815-15-25, the election can be made at the inception of a financial instrument to account for the instrument under the fair value option under ASC 825 “Financial Instruments – Overall” (“ASC 825”). The Company has made such election for its Convertible Promissory Note. Using the fair value option, the Convertible Promissory Note is required to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the note are recognized as non-cash within change in the fair value of the Convertible Promissory Note in the statements of operations. On November 2, 2023, the Convertible Promissory Note was terminated and of no further force and effect, resulting in loan forgiveness by the note holder. For the terminated Convertible Promissory Note, the Company followed ASC 470 “Debt” (“ASC 470”). As a result, the Convertible Promissory Note was assigned a value of zero upon termination of the note.

At ~~December~~As ~~31, 2023, as~~ the holders of the Convertible Promissory Notes are equity holders in the Company, upon the ~~resulting~~termination ~~gain~~ of ~~$988,402~~the onConvertible Promissory Note, the ~~extinguishment~~Company ofrecognized ~~the~~a ~~Convertible~~gain ~~Promissory~~of ~~Note~~$988,402 ~~was~~and ~~included~~reported ina deemed contribution by the Former Sponsor on the statement of changes in stockholders’ deficit.

On February 26, 2024, the Company issued the FI Sponsor Promissory Note to the Sponsor in the total principal amount of up to $500,000. The FI Sponsor Promissory Note does not bear interest and matures upon closing of the Company’s Initial Business Combination. In the event that the Company does not consummate an Initial Business Combination, the FI Sponsor Promissory Note will be repaid only from amounts remaining outside of the Trust Account. Up to the total principal amount of the FI Sponsor Promissory Note may be converted, in whole or in part, at the option of the lender into warrants of the Company at a price of $1.50 per warrant, which warrants will be identical to the Private Placement Warrants issued to the Former Sponsor at the time of the initial public offering of the Company.

The option (“Working Capital Loan Option”) to convert the FI Sponsor Promissory Note into warrants qualifies as an embedded derivative under ASC 815 and is required to be reported at fair value. At ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, the value of the Working Capital Loan Option was $0.

Related Party Promissory Note

On July 31, 2023, the Company issued a non-interest bearing promissory note in the aggregate principal amount of up to $1,052,644 (“Related Party Promissory Note”) to the Former Sponsor and borrowed a net amount of $400,009.

On November 2, 2023, $335,259 of the Related Party Promissory Note was terminated and of no further force and effect, resulting in loan forgiveness by the note holder. For the terminated Related Party Promissory Note, the Company followed ASC 470. ~~As a result, at December 31, 2023, the Company reported $64,749 on the balance sheet on the line due to related party.~~ During the first quarter of 2024, the Former Sponsor was repaid $64,749 and subsequently paid certain expenses on behalf of the company. As such, at ~~September~~March 3031, 2025 and December 31, 2024, the Company reported $27,500 on the consolidated condensed balance ~~sheet~~sheets on the line due to related party.

As the holders of the Related Party Promissory Notes are equity holders in the Company, the resulting gain on the extinguishment of the Related Party Promissory Note was recognized as a capital contribution to the Company during the ~~fourth~~year ~~quarter~~ended 2023.

Due to related party

A related party paid certain expenses on behalf of the Company with the amount due upon demand. At September 30, 2024 and December 31, 2023, the related party was due $27,500 and $64,750 respectively.

Non-Redemption Agreement

The Company has determined the non-redemption agreements entered into in connection with the October 2023 Special Meeting are an equity classified derivative instrument. As such, the Company complies with the requirements of SEC Staff Accounting Bulletin (“SAB”) Topic 5(T): Miscellaneous Accounting - Accounting for Expenses or Liabilities Paid by Principal Stockholder(s). AsUpon ~~such,~~issuance ~~at December~~on 31October 6, 2023, the value of the 389,359 Class B common stock, determined to be $1,230,000, transferred to the non-redeeming shareholders is treated as an equity contribution and recognized as operating costs in the statement of operations. ~~The value of the Class B common stock forfeited by the Sponsors is reported as an increase to stockholders’ equity.~~

The Company has determined the 2024 Non-Redemption Agreements entered into in connection with the July 2024 Special Meeting are a liability classified derivative instrument. As such, the 2024 Non-Redemption Agreements were recognized at fair value at inception of the ~~of the~~ agreements and remeasured to fair value at ~~September~~March 3031, 2025 and December 31, 2024 with the change in fair value recognized in the consolidated condensed statement of operations.

Subscription Agreement

On November 3, 2023, the Company entered into a subscription agreement (the “Subscription Agreement”) with the Sponsor and Polar, pursuant to which Polar agreed to make certain capital contributions to the Company of up to $1,200,000 (the “Capital Contribution”) at the request of the Company. The Capital Contribution shall be repaid to Polar by the Company within five (5) business days of the Company closing an Initial Business Combination (the “Closing”). Polar may elect to receive such repayment (i) in cash or (ii) in shares of common stock of the surviving entity in such Initial Business Combination (the “Surviving Entity”). Additionally, in consideration of the Capital Contribution, at the Closing, the Surviving Entity will issue to Polar one share of common stock for each dollar of Capital Contribution that is funded prior to the Closing (“Subscribed Shares”). The Subscription Agreement includes two separate transactions– a promissory note (“Note Payable – Polar”) and a share subscription agreement (“SSA – Polar”).

In accordance with ASC 825, the Company has elected to record the Note Payable – Polar at fair value upon issuance and will remeasure the Note Payable – Polar at fair value at each reporting period. Changes in the estimated fair value of the Note Payable – Polar are recognized within change in the fair value of the Note payable – Polar in the statements of operations. At March 31, 2025 and December 31, 2024, the Company had borrowed $1,200,000 under the Subscription Agreement and reported the fair value of the Note Payable - Polar on the consolidated condensed balance sheets of $ 1,066,792 and $849,839, respectively. For the three months ended March 31, 2025 and 2024, the Company recognized a loss of $216,953 and $95,986 in the consolidated condensed statement of operation related to the Note Payable - Polar.

In accordance with ASC 825, the Company has elected to record the Note Payable – Polar at fair value upon issuance and will remeasure the Note Payable – Polar at fair value at each reporting period. Changes in the estimated fair value of the Note Payable – Polar are recognized within change in the fair value of the Note payable – Polar in the statements of operations. At September 30, 2024, the Company had borrowed $1,200,000 under the Subscription Agreement and reported the fair value of the Note Payable - Polar on the balance sheet of $624,686. At December 31, 2023, there was $850,000 borrowed under the Subscription Agreement. The Note Payable – Polar is remeasured to fair value at each reporting date. Changes in fair value of $13,745 and $(96,577) were included in the statement of operations during the three and nine months ended September 30, 2024, respectively.

The SSA – Polar is indexed and settled in the Company’s common stock and is thus considered an equity classified instrument under ASC815. The following table shows the activity of the Note Payable - Polar.

			Discount to Fair Value				Change in Fair Value
	Borrowing		(Equity)		Fair Value		Gain/(Loss)
November 3, 2023	$	850,000	$	590,851	$	259,149
December 31, 2023					$	346,353	$	(87,204	)
March 12, 2024	$	250,000	$	120,592	$	129,408
March 31, 2024					$	571,747	$	(95,986	)
May 2, 2024	$	100,000	$	47,652	$	52,348
June 30, 2024					$	638,431	$	(14,336	)
September 30, 2024					$	624,686	$	13,745

Capital Market Advisors

In 2023, the Company engaged the services of multiple entities to act as capital market advisors (“CMA”), specifically to advise on market conditions, seeking an extension for completing an Initial Business Combination, a possible Initial Business Combination, and acting as a placement agent in connection with a private placement of equity, equity-linked, convertible and/or debt securities or other capital or debt raising transaction. No fees are due the advisors until consummation of the Initial Business Combination and are payable at that time in a combination of cash and shares of common stock of the public company entity that survives the Initial Business Combination. In accordance with ASC 718, at the effective date of November 2, 2023, the value of the shares issuable as of the execution date of the contracts was $312,600. Additionally, the Company will pay $3,500,000 plus an amount equal to 4.0% (together the “Deferred CMA Fees”) of the sum of (A) the gross proceeds raised from investors identified by the advisor received by the Company or Target plus (B) proceeds released from the Trust Account in connection with the closing of the Initial Business Combination with respect to any stockholder of the Company that (x) entered into a non-redemption or other similar agreement or (y) did not redeem shares of the Company’s Class A common stock.

In accordance with ASC Topic 450, “Contingencies,” (“ASC 450”), the Company has not recognized a liability for the value of the potential issuance of shares or the Deferred CMA Fees since the completion of an Initial Business Combination is a performance condition that is ~~not~~subject ~~yet~~to ~~considered~~significant ~~probable~~external contingencies with a high degree of uncertainty.

Derivative Warrant Liabilities

The Company evaluated the Public Warrants and Private Placement Warrants (collectively, “Warrant Securities”) in accordance with ASC 815-40 Derivatives and Hedging—Contracts in Entity’s Own Equity,” and concluded that the Warrant Securities could not be accounted for as components of equity. As the Warrant Securities meet the definition of a derivative in accordance with ~~ASC815~~ASC 815-40, the Warrant Securities are recorded as derivative liabilities on the balance sheets and measured at fair value at issuance and remeasured at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the statements of operations in the period of change.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Shares of conditionally redeemable Class A common stock (including Class A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, shares of Class A common stock are classified as stockholders’ equity. The Company’s Class A common stock features include certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at ~~September~~March 3031, ~~2024~~ 2025 and December 31, ~~2023~~2024, 1,212,124 ~~and 2,312,029~~ shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ ~~equity~~deficit section of the ~~accompanying~~consolidated condensed balance sheets~~, respectively~~.

All of the 23,000,000 shares of Class A common stock sold as part of the Units in the Initial Public Offering (1,212,124 of which remained outstanding after giving effect to the First Redemption, the Second Redemption and the Third Redemption and excluding 4,100,000 shares of non-redeemable Class B common stock that has been converted into non-redeemable shares of Class A common stock) contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation if there is a stockholder vote or tender offer in connection with the Initial Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Accretion of redeemable common stock results in charges against accumulated deficit.

Changes in the carrying amount of common stock subject to redemption are affected by earnings on the Trust Account that exceed amounts payable for taxes, additional funding of the Trust Account, amounts withdrawn from the Trust Account to pay tax obligations and redemptions of the Company’s Class A common stock.

Purchase of Shares by Sponsor

Pursuant to the closing of the Purchase Agreement, the Sponsor agreed to purchase an aggregate of 3,746,303 shares of Class B common stock from the Former Sponsor and each of the anchor investors and 4,160,000 private placement warrants from the Former Sponsor for an aggregate purchase price of $16,288. The Company accounts for the value of the shares acquired in excess of the purchase price in accordance with ASC 340 “Other Assets and Deferred Costs” (“ASC 340”). Management of the Company determined the fair value of the Class B common stock and Private Placement Warrants acquired to be $11,892,328. The excess value of the Class B common stock and Private Placement Warrants acquired was $11,876,040.

Reimbursable Expenses

The Company recognized the Reimbursable Expenses following ASC 805 in accordance with the nature of the costs originally incurred. As such, expenses reimbursed to the Company or paid for on behalf of the Company are reported as a reduction of expenses incurred by the Company on the ~~consolidated~~ condensed consolidated statement of operations. Due to uncertainty in collections of the reimbursable expenses, the Company recognizes a reduction of expenses when received. For the three months ended March 31, 2025 and 2024, the Company is reporting a reduction in operating costs of $163,982 and $0, respectively,

For the three and nine months ended September 30, 2024, the Company is reporting a reduction in operating costs $217,232 related to the Reimbursable Expenses. For the three and nine months ended September 30, 2023, the Company is reporting a reduction in operating costs of $0 related to the Reimbursable Expenses. Other than the reimbursement of expenses discussed herein, as of September 30, 2024, no other invoices or related support has been presented to XCF for payment or reimbursement.

Income Taxes

The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company’s operations included those activities necessary to consummate an Initial Business Combination. As such, the Company deducted startup and operating costs for tax purposes. Additionally, the Company has taken the position that no income should the apportioned to Florida in its Florida state tax return. As there is uncertainty in the deduction of startup and operating costs and the apportionment of income to the State of Florida, the Company recognized a reserve for uncertain tax positions on the consolidated condensed balance ~~sheet~~sheets in 2023. In 2024, the Company reversed its position related to the deductibility of start-up and operating costs for tax purposes and no longer reports an uncertain tax position for these items. The Company continues to take the position that no income should the apportioned to Florida in its Florida state tax return. As such, the Company maintains an uncertain tax position related to its Florida tax return. At ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, the Company reported $115,870 ~~and~~on ~~$955,617,~~the ~~respectively,~~consolidated ~~on the~~condensed balance ~~sheet~~sheets for these uncertainty.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s ~~unaudited~~condensed consolidated ~~condensed~~ financial statements.

Risks and Uncertainties

The Company’s results of operations and ability to complete an Initial Business Combination may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond the Company’s control. The Company’s business could be impacted by, among other things, downturns in the financial markets or in economic conditions, increases in oil prices, inflation, increases in interest rates, supply chain disruptions, declines in consumer confidence and spending and geopolitical instability, such as the military conflict in the Ukraine. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business and the Company’s ability to complete an Initial Business Combination.

Inflation Reduction Act of 2022

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023 (the “Excise Tax”). The Excise Tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the Excise Tax.

Table of Contents

The U.S. Department of the Treasury (the “Treasury”) has authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of, the Excise Tax. Any redemption or other repurchase that occurs after December 31, 2023, in connection with a Business Combination, extension vote or otherwise, may be subject to the Excise Tax.

Whether and to what extent the Company would be subject to the Excise Tax will depend on a number of factors, including (i) whether the redemption is treated as a repurchase of stock for purposes of the Excise Tax, (ii) the fair market value of the redemptions treated as repurchases in connection with a Business Combination, (iii) the structure of a Business Combination and whether any such transaction closes, (iv) the nature and amount of any private investment in public equity (“PIPE”) or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination), and (v) the content of regulations and other guidance issued by the Treasury. It is possible that the Company will be subject to the Excise Tax with respect to any subsequent redemptions, including redemptions in connection with the Business Combination, that are treated as repurchases for this purpose (other than, pursuant to recently issued guidance from the Treasury, redemptions in complete liquidation of the Company). As mentioned, the Excise Tax is imposed on the repurchasing corporation itself, not the stockholders from which stock is repurchased. The imposition of the Excise Tax (including as a result of public stockholders electing to exercise their redemption rights in connection with an Business Combination) could, however, reduce the amount of cash available to the Company to pay redemptions (or the cash contribution to the target business in connection with our Business Combination, which could hinder the Company’s ability to complete a Business Combination or cause the other stockholders of the combined company to economically bear the impact of such Excise Tax).

During the second quarter of 2024, the IRS issued final regulations with respect to the timing and payment of the Excise Tax. Pursuant to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December 31, 2023 on or before October 31, 2024.

The 2023 Excise Tax return and payment is normally due on October 31, 2024, however, due to the Company’s tax preparer being located in a Texas disaster area related to Hurricane Beryl, the Company’s 2023 Excise Tax return and payment iswas not due until February 2025. As of the filing of this Form 10-Q, no Excise Tax payments have been paid and the Company has incurred $15,744 in interest and penalties reported in operating costs on the consolidated condensed statement of operations.

The Company is currently evaluating its options with respect to payment of this obligation. If the Company is unable to pay its obligation in full, it will be subject to additional interest and penalties which are currently estimated at 107% interest per annum and a 4.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from February 2025 until paid in full.

Net (Loss) ~~Income~~ Per Common Stock

The Company has two classes of shares outstanding, which are referred to as redeemable Class A common stock and non-redeemable Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of common stock. Basic net (loss) ~~income~~ per share of common stock is calculated by dividing the net (loss) ~~income~~ attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net (loss) ~~income~~ per share is computed by dividing the net (loss) ~~income~~ attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net (loss) ~~income~~ per share calculation the warrants to purchase common stock and the shares issuable in accordance with the Subscription Agreement are considered to be potentially dilutive securities pursuant to the treasury stock method. In order to determine the net (loss) ~~income~~ attributable to both the redeemable Class A common stock and the non-redeemable Class A common stock and Class B common stock, the Company first considered the total income allocable to both sets of shares. This is calculated using the total net (loss) ~~income~~ less any dividends paid. For purposes of calculating net (loss) ~~income~~ per share, any change to the redemption value of the redeemable Class A common stock is treated as a deemed dividend for the purposes of the numerator in the earnings per share calculation, as the redemption value approximates fair value. Additionally, the excise tax payable is treated as a deemed dividend as the activity of redeeming shares that generates the excise tax is done for the benefit of the redeemable Class A common stockholders. Subsequent to calculating the total income allocable to both sets of shares, the Company calculates the amount to be allocated pro rata between the redeemable Class A common stock and non-redeemable Class A common stock and Class B common stock for each of the periods presented.

The following table reflects the calculation of basic and diluted net income per share of common stock (in dollars, except per share amounts):

	For the Three Months September 30,						For the Nine Months September 30,
	For the Three Months Ended March 31,
	2024			2023			2024			2023
	2025			2024
Net (loss) income, as reported	$	(1,006,971	)	$	(701,173	)	$	(4,960,533	)	$	1,782,882
Net loss, as reported	$	(1,426,442	)	$	(2,504,756	)
Reconciliation items:
Deemed dividend to redeemable Class A stockholders		~~(308~~47,~~051~~214	)		(~~415~~358,~~659~~656	)		~~(736,696~~	)		~~(2,220,336~~	)
Allocation of net loss, as adjusted	$	(1,~~315~~473,~~022~~656	)	$	(12,~~116~~863,~~832~~412	)	$	~~(5,697,299~~	)	$	~~(437,454~~	)

	For the Three Months Ended September 30,
	For the Three Months Ended March 31,
	2024								2023
	2025								2024
	Redeemable Class A	~~Redeemable Class A~~			Non-redeemable Class A and Class B	~~Non-redeemable Class A and Class B~~			Redeemable Class A	~~Redeemable Class A~~			Non-redeemable Class A and Class B	~~Non-redeemable Class A and Class B~~
Basic and diluted net loss per share:
Numerator:
Allocation of net loss attributable to common stockholders, as adjusted	$	$(258,112	~~(282,548~~)	)	$	$(1,215,544	~~(1,032,474~~)	)	$	$(822,198	~~(520,156~~)	)	$	$(2,041,214	~~(596,676~~)	)
Allocation of accretion of temporary equity to redeemable Class A shares		47,214	~~308,051~~			—	—			358,656	~~415,659~~			—	—
Allocation of net loss	$	$(210,898	~~25,503~~)		$	$(1,215,544	~~(1,032,474~~)	)	$	$(463,542	~~(104,497~~)	)	$	$(2,041,214	~~(596,676~~)	)
Denominator:
Weighted average common stock outstanding, basic and diluted		1,212,124	~~1,570,789~~			5,708,333	~~5,739,916~~			2,312,029	~~5,012,592~~			5,739,916	~~5,750,000~~
Basic and diluted net loss per common share	$	$(0.17	~~0.02~~)		$	$(0.21	~~(0.18~~)	)	$	$(0.20	~~(0.02~~)	)	$	$(0.36	~~(0.10~~)	)

	For the Nine Months Ended September 30,
	2024						2023
	Redeemable Class A			Non-redeemable Class A and Class B				Redeemable Class A			Non-redeemable Class A and Class B
Basic and diluted loss income per share:
Numerator:
Allocation of net loss attributable to common stockholders, as adjusted	$	(1,506,359	)	$	(4,190,870	)		$	(203,741	)	$	(233,713	)
Allocation of accretion of temporary equity to redeemable Class A shares		736,696			—				2,220,336			—
Allocation of net (loss) income	$	(769,663	)	$	(4,190,870	)		$	2,016,595		$	(233,713	)
Denominator:
Weighted average common stock outstanding, basic and diluted		2,063,145			5,739,916				5,012,592			5,750,000
Basic and diluted net (loss) income per common share	$	(0.37	)	$	(0.73	)		$	0.40		$	(0.04	)

As of March 31, 2025 and 2024, the outstanding warrants to purchase 17,900,000 shares of Class A common stock were excluded from the computation of diluted net loss per share of common stock for the periods presented as the exercise price is greater than the average market price (out of the money) and their inclusion would be anti-dilutive under the treasury stock method. Additionally, as of March 31, 2025, 73,333 warrants that may be issued upon exercise of the FI Sponsor Promissory Note conversion option were excluded from the computation of diluted net income per share of common stock as the warrants were out of the money and their inclusion would be anti-dilutive under the treasury stock method. At March 31, 2025 and December 31, 2024, 1,320,000 shares of Class A common stock that may be issued in association with the Subscription Agreement are excluded from diluted net loss per share as the conditions for the issuance of the shares has not happened. Additionally, shares that might be issuable in relation to the proposed Business Combination are excluded from the diluted net loss per share as the conditions for the issuance of the shares has not happened.

As of September 30, 2024 and 2023, the outstanding warrants to purchase 17,900,000 shares of Class A common stock were excluded from the computation of diluted net income per share of common stock for the periods presented as the exercise price is greater than the average market price (out of the money) and their inclusion would be anti-dilutive under the treasury stock method. At September 30, 2024 and 2023, 1,320,000 and 0 shares of Class A common stock, respectively, that may be issued in association with the Subscription Agreement are excluded from diluted net income per share as the conditions for the issuance of the shares has not happened. Additionally, shares that might be issuable in relation to the proposed Business Combination are excluded from the diluted net income per share as the conditions for the issuance of the shares has not happened.

Note 3—Related Party Transactions

Founder Shares

Prior to the Initial Public Offering, the Former Sponsor and directors (the “Initial Stockholders”) purchased an aggregate of 5,750,000 shares of Class B common stock, par value $0.0001 per share (“Class B common stock,” “Class B Shares” or “founder shares”) for an aggregate purchase price of $25,000, or approximately $0.004 per share. Prior to the initial investment in the Company of $25,000 by our Initial Stockholders, the Company had no assets, tangible or intangible. The per share purchase price of the founder shares was determined by dividing the amount of cash contributed to the Company by the aggregate number of founder shares issued. The initial stockholders (including the anchor investors) collectively owned 20% of the outstanding shares of common stock following the Initial Public Offering. Certified qualified institutional buyers or institutional accredited investors, as defined in Rule 144A and Regulation D, respectively, under the Securities Act, which are not affiliated with the Company, the Former Sponsor, the Company’s directors or any member of management and that purchased an aggregate of approximately 22,980,000 units in the Initial Public Offering at the public offering price (“herein referred to as “anchor investor”) purchased the number of Units for which it had provided an indication of interest (not to exceed 9.9% of the units sold in the Initial Public Offering). In consideration of these purchases, the Former Sponsor entered into an investment agreement with each of the anchor investors pursuant to which the Former Sponsor sold 1,450,758 founder shares in the aggregate, at their original purchase price of approximately $0.004 per share.

The founder shares are identical to the shares of the Class A common stock included in the Units sold in the offering, except that:


	•	prior to the Company’s Initial Business Combination, only holders of the founder shares have the right to vote on the election of directors and holders of a majority of the founder shares may remove a member of the board of directors for any reason;


	•	the founder shares are subject to certain transfer restrictions, as described in more detail below;

• each of the Company’s Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive (i) their redemption rights with respect to their founder shares and any public shares held by them in connection with the completion of the Initial Business Combination; (ii) their redemption rights with respect to their founder shares and any public shares held by them in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of its obligation to allow redemption in connection with the Initial Business Combination or to redeem 100% of the public shares if the Company has not completed an Initial Business Combination on or before ~~February~~April 7, 2025 (as ~~may be~~ extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors) or (B) with respect to any other provisions relating to stockholders’ rights or pre-Initial Business Combination activity; and (iii) their rights to liquidating distributions from the Trust Account with respect to any founder shares held by them if the Company does not complete the Initial Business Combination on or before ~~February~~April 7, 2025 (as ~~may be~~ extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors), although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company does not complete the Initial Business Combination within the prescribed time frame. If the Company submits the Initial Business Combination to its public stockholders for a vote, the Sponsor, officers and directors have agreed to vote their founder shares and any public shares they may acquire during or after the Initial Public Offering, in favor of the Initial Business Combination, and each of the anchor investors has agreed to vote its founder shares (subject to the right to abstain from voting) in favor of the Initial Business Combination.


	•	the founder shares are shares of Class B common stock that will automatically convert into shares of the Company’s Class A common stock upon the completion of the Initial Business Combination or earlier at the option of the holder thereof;

• the anchor investors will not be entitled to (i) redemption rights with respect to any founder shares held by them in connection with the completion of the Initial Business Combination; (ii) redemption rights with respect to any founder shares held by them in connection with a stockholder vote to amend the Company’s amended and restated certification of incorporation in a manner that would affect the substance or timing of its obligation to redeem 100% of our public shares if the Company has not consummated an Initial ~~business~~Business ~~combination~~Combination by ~~February~~April 7, 2025 (as ~~may be~~ extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors) or; (iii) rights to liquidating distributions from the Trust Account with respect to any founder shares held by them if the Company fails to complete its Initial Business Combination by ~~February~~April 7, 2025 (as ~~may be~~ extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors) (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the Initial Business Combination within the prescribed time frame); and


	•	the founder shares are entitled to registration rights.

Transfer restrictions on founder shares

Holders of the Company’s founder shares (including the anchor investors) have agreed not to transfer, assign or sell any of their founder shares and any shares of our Class A common stock issuable upon conversion thereof until the earlier to occur of: (i) one year after the completion of our Initial Business Combination; and (ii) subsequent to the Initial Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our Initial Business Combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of the public stockholders having the right to exchange their shares of common stock for cash, securities or other property (except to certain permitted transferees and under certain limited circumstances). Any permitted transferees will be subject to the same restrictions and other agreements of our initial stockholders with respect to any founder shares (except that the anchor investors will be permitted to abstain from voting founder shares).

Transfer restrictions on founder shares

In conjunction with each anchor investor purchasing 100% of the Units allocated to it, in connection with the closing of the Initial Public Offering, the Former Sponsor sold an aggregate of 1,450,758 founder shares at their original purchase price. The Company estimated the fair value of the founder shares attributable to the anchor investors to be $9.3 million or $6.40 per share as of October 7, 2021 (date of the Initial Public Offering).

The excess of the fair value of the founder shares sold over the purchase price of $5,803 (or $0.004 per 1,450,758 share) was determined to be an issuance cost of the Initial Public Offering incurred on the Company’s behalf. Accordingly, this issuance cost as well as Offering Costs were accounted for as an equity contribution from the Former Sponsor. As a portion of the Initial Public Offering consisted of Warrant Securities that are accounted for as liabilities, as such the fair value of the 1,450,758 founder shares sold to the anchor investors by the Former Sponsor ($0.6 million) was allocated to the warrant liabilities as of October 7, 2021 (date of Public Offering).

On November 2, 2023, the Sponsor acquired an aggregate of 3,746,303 shares of Class B common stock from the Former Sponsor and each of the anchor investors and 4,160,000 private placement warrants from the Former Sponsor. Contemporaneously with the shares acquired by the Sponsor, the Sponsor transferred an aggregate of 50,000 shares of Class B common stock to two of the Company’s directors.

In connection with the October 2023 Special Meeting the Former Sponsor converted 3,000,000 of its shares of Class B common stock into shares of Class A common stock. Upon conversion of shares of Class B common stock to shares of Class A common stock, such shares of Class A common stock are not entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions.

In connection with the July 2024 Special Meeting, the Sponsor and Former Sponsor converted an aggregate of 1,100,000 of their shares of Class B common stock into shares of Class A common stock. Upon conversion of shares of Class B common stock to shares of Class A common stock, such shares of Class A common stock are not entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions.

Private Placement Warrants

Simultaneously with the Initial Public Offering, the Former Sponsor purchased an aggregate of 6,400,000 Private Placement Warrants at $1.50 per Private Placement Warrant, for an aggregate purchase price of $9,600,000. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 (subject to adjustment in certain circumstances). The net proceeds from the Private Placement Warrants of $2,300,000 were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete an Initial Business Combination within the Combination Period, the net proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants: (i) will not be redeemable by the Company so long as they are held by the Former Sponsor or Sponsor or any of its permitted transferees; (ii) may be exercised for cash or on a cashless basis, so long as they are held by the Former Sponsor or Sponsor or any of its permitted transferees and (iii) are (including the common stock issuable upon exercise of the Private Placement Warrants) entitled to registration rights. Additionally, the Former Sponsor and Sponsor have agreed not to transfer, assign or sell any of the Private Placement Warrants, including the Class A common stock issuable upon exercise of the Private Placement Warrants (except to certain permitted transferees), until 30 days after the completion of the Initial Business Combination.

Indemnity

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company discussed entering into a transaction agreement, reduces the amount of funds in the Trust Account to below (i) $10.10 per public share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor’s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such eventuality as the Company believes the likelihood of the Sponsor having to indemnify the Trust Account is limited because the Company will endeavor to have all vendors and prospective target businesses as well as other entities execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Convertible Promissory Notes

In order to finance transaction costs in connection with the Initial Business Combination, on November 1, 2022 the Former Sponsor executed an unsecured Convertible Promissory Note and agreed to loan the Company up to $1,500,000 as may be required, the terms of which consist of no interest accrual and a maturity date commensurate with the date the Initial Business Combination has been consummated (“Working Capital Loans”). In the event that the Initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into warrants at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants issued to the Former Sponsor. Effective as of November 2, 2023, in connection with the closing of the transactions contemplated by the Purchase Agreement, the Convertible Promissory Note was forgiven by the note holder. For the year ended December 31, 2023, the Company recorded a $988,402 capital contribution included in deemed contribution by Former Sponsor on the statement of changes in stockholders’ deficit.

On February 26, 2024, the Company issued the FI Sponsor Promissory Note to the Sponsor. The Promissory Note does not bear interest and matures upon closing of the Company’s Initial Business Combination. In the event that the Company does not consummate an Initial Business Combination, the FI Sponsor Promissory Note will be repaid only from amounts remaining outside of the Trust Account. Up to the total principal amount of the FI Sponsor Promissory Note may be converted, in whole or in part, at the option of the lender into warrants of the Company at a price of $1.50 per warrant, which warrants will be identical to the Private Placement Warrants issued to the Former Sponsor at the time of the initial public offering of the Company. At ~~September~~March 3031, 2025 and December 31, 2024, there was $110,000 outstanding on the FI Sponsor Promissory Note.

Table of Contents

Administrative Services Agreement

The Company entered into an agreement whereby, commencing on October 7, 2021, through the earlier of the consummation of an Initial Business Combination or the Company’s liquidation, the Company has agreed to pay an affiliate of the Former Sponsor a monthly fee of $15,000 for office space, utilities and administrative support. The Company records the administrative services agreement costs within operating costs on the statements of operations. On August 8, 2023, (i) the Company and the Former Sponsor agreed to terminate the Administrative Services Agreement dated October 4, 2021, with effect from and as of March 31, 2023 and (ii) the Former Sponsor agreed to waive any and all amounts due and owing by the Company after March 31, 2023. For the three and nine months ended September 30, 2024, the Company did not incur any fees related to the administrative services agreement. For the three and nine months ended September 30, 2023, the Company incurred and paid $0, and $45,000, respectively.

Note 4—Stockholders’ Deficit

Preferred Stock

The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors may, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the Common Stock and could have anti-takeover effects. At ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, there were no shares of preferred stock issued or outstanding.

Common Stock

The Company is authorized to issue 200,000,000 Class A Shares, with a par value of $0.0001 each, and 20,000,000 Class B common stock, with a par value of $0.0001 each (the “Class B Shares” and, together with the Class A Shares, the “Common Stock”). Holders of the Common Stock are entitled to one vote for each share of Common Stock; provided that only holders of the Class B Shares have the right to vote on the election of directors prior to the Initial Business Combination. The Class B Shares will automatically convert into Class A Shares at the time of the Initial Business Combination, on a one-for-one basis, subject to adjustment for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein.

In the case that additional Class A Shares, or equity-linked securities, are issued or deemed issued in excess of the amounts sold in the Initial Public Offering and related to the closing of the Initial Business Combination, the ratio at which the Class B Shares shall convert into Class A Shares will be adjusted (unless the holders of a majority of the outstanding Class B common stock agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A Shares issuable upon conversion of all Class B Shares will equal, in the aggregate, 20% of the sum of all Common Stock outstanding upon completion of the Initial Public Offering plus all Class A Shares and equity-linked securities issued or deemed issued in connection with the Initial Business Combination, excluding any Common Stock or equity-linked securities issued, or to be issued, to any seller in the Initial Business Combination, or any Private Placement-equivalent Warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company.

In connection with the October 2023 Special Meeting the Former Sponsor converted 3,000,000 of its shares of Class B common stock into shares of Class A common stock and in connection with the July 2024 Special Meeting the Sponsor and Former Sponsor converted an aggregate of 1,100,000 of their shares of Class B common stock into shares of Class A common stock.

The redemption value for Class A common stock subject to possible redemption reflected on the balance sheets is reconciled on the following table:

	Shares				~~Amount~~	Amount
December 31, 2022		5,012,592			$	50,125,920
December 31, 2023			2,312,029			$	24,005,323
Less:
Redemption of Class A common stock		~~(2,700,563~~	)(1,099,905	)		~~(28,393,290~~	)(11,692,068	)
Plus:
Accretion of Class A common stock to redemption value		—	—			~~2,272,693~~	953,596
December 31, 2023		2,312,029			$	24,005,323
December 31, 2024			1,212,124				13,266,851
Plus:
Accretion of Class A common stock to redemption value		—	—			~~358,656~~	47,214
March 31, 2024		2,312,029			$	24,363,979
March 31, 2025			1,212,124			$	13,314,065
Plus:
Accretion of Class A common stock to redemption value		—				69,989
June 30, 2024		2,312,029			$	24,433,968
Less:
Redemption of Class A common stock		(1,099,905	)			(11,692,068	)
Plus:
Accretion of Class A common stock to redemption value		—				191,130
September 30, 2024		1,212,124			$	12,933,030

Warrants

Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of an Initial Business Combination or (b) 12 months from the closing of the Initial Public Offering, provided in each case that the Company has an effective registration statement under the Securities Act covering the sale of the shares of its Class A common stock issuable upon exercise of the warrants, and a current Offering prospectus relating thereto is available, and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement as a result of (i) the Company’s failure to have an effective registration statement by the 60th business day after the closing of the Initial Business Combination as described in the immediately following paragraph or (ii) a notice of redemption described below). The Public Warrants will expire five years after the completion of an Initial Business Combination or earlier upon redemption or liquidation. At ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, there were 11,500,000 Public Warrants and 6,400,000 Private Placement Warrants outstanding.

Table of Contents

The Company is not obligated to deliver any Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue any Class A common stock upon exercise of a warrant unless Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of an Initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the sale of the shares of Class A common stock issuable upon exercise of the Warrants, and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the Warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the sale of the shares of Class A common stock issuable upon exercise of the Warrants is not effective by the 60th business day after the closing of the Initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the shares of Class A common stock at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will be required to use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Redemption of Warrant Securities when the price per share of Class A common stock equals or exceeds $18.00

Once the Warrant Securities become exercisable, the Company may redeem the outstanding Warrant Securities (except as described herein with respect to the Private Placement Warrants):


	•	in whole and not in part;


	•	at a price of $0.01 per Warrant Security;

• upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and


	•	if, and only if, the last reported sale price of our Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Warrant Securities’ holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities).

The Company will not redeem the Warrant Securities as described above unless an effective registration statement under the Securities Act covering the sale of the shares of Class A common stock issuable upon exercise of the Warrant Securities is effective, and a current prospectus relating thereto is available, throughout the 30-day redemption period. Any such exercise would not be on a “cashless basis” and would require the exercising Warrant Security holder to pay the exercise price for each Warrant Security being exercised.

Except as set forth below, none of the Private Placement Warrants will be redeemable by the Company so long as they are held by the Sponsor or its permitted transferees.

Redemption of Warrant Securities when the price per share of Class A common stock equals or exceeds $10.00

Once the Warrant Securities become exercisable, the Company may also redeem the outstanding Warrant Securities (except as described herein with respect to the Private Placement Warrants):


	•	in whole and not in part;


	•	at $0.10 per Warrant Security upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of the Class A common stock;


	•	if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity-linked securities); and


	•	if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like and certain issuances of Class A common stock and equity- linked securities), the Private Placement Warrants must also concurrently be called for redemption on the same terms as the outstanding Public Warrants, as described above.

The “fair market value” of the Class A common stock means the volume-weighted average price of the Class A common stock for the ten trading days immediately following the date on which the notice of redemption is sent to the holders of Warrant Securities. The Company will provide its Warrant Security holders with the final fair market value no later than one business day after the 10-day trading period described above ends. In no event will the Warrant Securities be exercisable in connection with this redemption feature for more than 0.361 shares of our Class A common stock per Warrant Security (subject to adjustment).

Table of Contents

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete an Initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (i) we issue additional common stock or equity-linked securities for capital raising purposes in connection with the closing of our Initial Business Combination at a Newly Issued Price of less than $9.20 per common stock, (ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our Initial Business Combination on the date of the completion of our Initial Business Combination (net of redemptions), and (iii) the Market Value is below $9.20 per share, then the exercise price of the warrants will be adjusted to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively.

Note 5—Fair Value Measurements

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are remeasured and reported at fair value at each reporting period. The following table presents information about the Company’s assets and derivative liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

				September 30,				December 31
	Level					March 31,2025				December 31,2024
	Level			2024				2023
Assets:
Assets:
Investments held in Trust Account			1			$	13,825,381			$	13,699,805
Investment held in Trust Account		1		$	12,950,024			$	24,554,804
Liabilities:
Liabilities:
Public Warrants (1)			1			$	230,000			$	230,000
Public Warrants (1)		1		$	460,000			$	690,000
Private Placement Warrants (1)			2			$	128,000			$	128,000
Private Placement Warrants (1, 2)		2		$	256,000			$	384,000
Working Capital Loan Conversion Option			3			$	—			$	—
Working Capital Loan Conversion Option		3		$	—			$	—
Note Payable - Polar			3			$	1,066,792			$	849,839
Note Payable - Polar		3		$	624,686			$	346,353
2024 Non-Redemption Agreements			3			$	1,240,000			$	1,250,000
2024 Non-Redemption Agreements		3		$	920,000			$	—

(1) The Warrants are accounted for as liabilities in accordance with ASC 815 and are presented within warrant liabilities on the condensed consolidated condensed balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated condensed statements of operations.

(2) Reclassified to level 2 on December 31, 2023

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Because of the inherent uncertainty of valuation, those estimated values may be materially higher or lower than the values that would have been used had a ready market for the investments existed. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for investments categorized in Level 3.

Warrant Liability

As of ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023~~2024, the Public Warrants are classified as Level 1 in the fair value hierarchy and are valued at the publicly traded price. The Private Placement Warrants have substantially the same terms as the Public Warrants and the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. With the decline in volatilities, there is de minimis benefit to Private Warrants with exemption from make whole redemptions. As such, the Private Placement Warrants are considered economically equivalent to the Public Warrants. Accordingly, the Private Placement Warrants are valued at the Public Warrant price and ~~on December 31, 2023~~ classified ~~them~~ as Level 2 financial instruments. ~~Other~~There ~~than the reclassification of the Private Placement Warrants to Level 2, there~~ were no ~~other~~ transfers in or out of Level 3 of the fair value hierarchy during period ended ~~September~~March 3031, 2025 or December 31, 2024.

Working Capital Loan Conversion Option

The Company’s FI Sponsor Promissory Note contains an embedded option (“Working Capital Loan Conversion Option”) whereby up to $1,500,000 of the FI Sponsor Promissory Note may be converted into the Company’s warrants. The embedded Working Capital Loan Conversion Option is accounted for as a liability in accordance with ACS 815-40 on the consolidated condensed balance ~~sheet~~sheets and is measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value in the consolidated condensed ~~statement~~ statements of operations. Valuation of the Working Capital Loan Conversion Option was derived from the valuation of the underlying Private Placement Warrants and is classified as a level 3 valuation.

Table of Contents

The following table presents the changes in the fair value of the Company’s financial assets and liabilities classified as Level 3:

	2024 Non- Redemption Agreements			Note ~~payable~~Payable - Polar			~~Working Capital Loan Conversion Option~~	Working Capital Loan Conversion Option
Fair value as of December 31, 2023	$	—		$	346,353		$	—
Fair value as of December 31, 2024	$	1,250,000		$	849,839			$	—
Initial value of the Working Capital Loan Conversion Option		—			—			—
Change in fair value		(10,000	)		216,953				—
Change in fair value		—			225,394			—
Fair value as of March 31, 2025	$	1,240,000		$	1,066,792			$	—
Fair value as of March 31, 2024	$	—		$	571,747		$	—
Change in fair value		—			66,684			—
Fair value as of June 30, 2024	$	—		$	638,431		$	—
Initial value of the 2024 Non-Redemption Agreements		1,002,000
Change in fair value		(82,000	)		(13,745	)		—
Fair value as of September 30, 2024	$	920,000		$	624,686		$	—

~~Convertible Promissory Notes~~25

Note Payable – Polar

At The ~~inception of the agreement and at December 31, 2023, the~~ Note Payable – Polar was valued using a bond plus call plus stock approach.

The model used for the Note Payable - Polar requires the use of subjective assumptions:

• The Risk-free rate as of the valuation date was selected based upon a typical equity investor assumed holding period.

• The expected volatility assumption was based on the implied volatility from the Company’s common stock and warrants. An increase in the expected volatility, in isolation, would result in an increase in the fair value measurement and vice versa.

• Probability of an Initial Business Combination as based on the Company’s management.

The key inputs into the models for the Note Payable - Polar were as follows:

Input	~~September~~March 3031, ~~2024~~2025			December 31, ~~2023~~2024
Probability of an Initial Business Combination		5090	%		4070	%
Risk-free rate		4.7335	%		54.1837	%
Expected term (years)		0.2517			0.5825
Expected volatility	~~De minimis~~	De minimis		~~De minimis~~	De minimis
Class A common stock price	$	106.5200		$	10.4622

2024 Non-Redemption Agreements

~~At inception of the 2024 Non-Redemption Agreements and at September 30, 2024,~~ ~~the~~ The 2024 Non-Redemption Agreements were valued using a likelihood-weighted scenario analysis.

The model used for the 2024 Non-redemption Agreements requires the use of subjective assumptions:

• The Risk-free rate as of the valuation date was selected based upon a typical equity investor assumed holding period.

• Probability of an Initial Business Combination as based on the Company’s management.

The key inputs into the models for the ~~Note~~2024 ~~Payable~~ Non-Redemption ~~Polar~~Agreements were as follows:

Input	~~September~~March 3031, ~~2024~~2025			December 31, 2024
Probability of an Initial Business Combination		5090	%		70	%
Risk-free rate		4.6730	%		4.32	%
Expected term (years)		0.2517			0.25
Expected volatility	~~De minimis~~	De minimis			De minimis
Class A common stock price	$	106.5200		$	10.22

2526

Note 6—Commitments

Registration Rights

Pursuant to a registration and stockholder rights agreement dated October 4, 2021, the holders of the founder shares, Private Placement Warrants (and their underlying securities) and the warrants that may be issued upon conversion of the Working Capital Loans (and their underlying securities) are entitled to registration rights. The holders of a majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of an Initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

~~Underwriters~~ On ~~Agreement~~February 20, 2025, the Company agreed to waive the lock-up restrictions and, as a result, none of the shares of the NewCo Common Stock that will be outstanding upon the completion of the Business Combination will be subject to any contractual restrictions on transfer of those shares.

~~The underwriters were paid a cash underwriting discount of 2.0%~~ of Note the gross proceeds of the Initial Public Offering, or $4.6 million. In addition, the underwriters were entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the Initial Public Offering, or $8,050,000. In connection with the closing of the Purchase Agreement, the Company received an irrevocable waiver by the underwriters for deferred underwriting discount. As a result, $7~~,548,450~~ — Segment ~~of the deferred underwriters’ fee was reversed through equity as it related to the Redeemable Class A common stock~~Information issued in the initial public offering and $501,550 of the deferred underwriters’ fee was reversed through the statement of operations as it related to the public warrants issued in the initial public offering.

~~Note~~ ASC ~~7—Subsequent~~Topic ~~Events~~280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

The Company’s ~~evaluated~~chief ~~subsequent~~operating ~~events~~decision ~~and~~maker ~~transactions~~has ~~that~~been ~~occurred~~identified ~~after~~as the ~~balance~~Chief ~~sheet~~Executive ~~date of September 30~~Officer, ~~2024~~who ~~through~~reviews the ~~date~~operating ~~that~~results ~~these~~for ~~unaudited consolidated~~the ~~condensed~~Company ~~financial~~as ~~statements~~a ~~were~~whole ~~issued.~~to ~~Based~~make ~~upon~~decisions ~~this~~about ~~review,~~allocating ~~the~~resources ~~Company~~and ~~did~~assessing ~~not~~financial ~~identify~~performance. ~~any~~Accordingly, ~~subsequent~~management ~~events~~has determined that ~~would have required adjustment or disclosure in~~ the ~~unaudited~~Company ~~consolidated~~only ~~condensed~~has ~~financial~~one ~~statements~~operating segment.

26 When evaluating the Company’s performance and making key decisions regarding resource allocation the CODM reviews key metrics, which include the following:


	For the Three Months Ended March 31, 2025		For the Three Months Ended March 31, 2024
Operating costs	$	1,295,159	$	2,646,244
Interest income – Trust Account	$	143,400	$	320,299

The key measures of segment profit or loss reviewed by our CODM are interest income – Trust Account and operating costs. The CODM reviews interest income – Trust Account to measure and monitor stockholder value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the trust agreement. Operating costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a Business Combination within the Combination period. The CODM also reviews operating costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.

Note 8—Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date of March 31, 2025 through the date that these consolidated condensed financial statements were issued. Based upon this review, other than as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

On April 4, 2025, BHAC, NewCo, Merger Sub 1, Merger Sub 2 and XCF entered into Amendment No. 2 to the Business Combination Agreement, which amends the Business Combination Agreement to extend the Termination Date from March 31, 2025 to May 31, 2025.

On April 7, 2025, the Company held the April 2025 Special Meeting to amend the Company’s amended and restated certificate of incorporation, as amended, to (i) extend the Termination Date from April 7, 2025 to May 7, 2025, and to allow the Company, without the need for another stockholder vote, to elect to extend the Termination Date on a monthly basis for up to five times, by an additional one month each time, after the Charter Extension Date, by resolution of the Company’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date. The stockholders of the Company approved the April 2025 Extension Amendment Proposal at the April 2025 Special Meeting. Following the April 2025 Special Meeting, the Company's board of directors has resolved to extend the Charter Extension Date until June 7, 2025.

In connection with the vote to approve the April 2025 Extension Amendment Proposal and the vote to approve the Business Combination, the holders of an aggregate of 1,208,635 shares of Class A common stock exercised their right to redeem their shares for cash at a redemption price of approximately $10.83 per share, for an aggregate redemption amount of approximately $13,094,093.

ITEM 2. ~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “us,” “our” or “we” refer to Focus Impact BH3 Acquisition Company. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and related notes included herein.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form 10-Q. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.

Overview

We are a blank check company incorporated on February 23, 2021 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We were initially incorporated under the name BH3 Acquisition Corp., and subsequently changed our name to Crixus BH3 Acquisition Company on July 21, 2021 and subsequently changed our name to Focus Impact BH3 Acquisition Company on November 3, 2023. We intend to effectuate our ~~Initial~~initial ~~Business~~business ~~Combination~~combination using cash from the proceeds of the ~~Initial~~initial ~~Public~~public ~~Offering~~offering and the ~~Private~~private ~~Placement Warrants~~placement warrants, our capital stock, debt or a combination of cash, stock and debt.

Recent Developments

On December 7, 2022 (following approval by our stockholders at the December 2022 Special Meeting), we effected a charter amendment and an amendment to its Investment Management Trust Agreement with Continental Stock Transfer & Trust Company, the effect of which was to change the Company’s prior termination date from April 7, 2023 to August 7, 2023 (as further extended to October 6, 2023 by the Former Sponsor providing the Company with the requisite notice and the deposit amount). In connection with the December 2022 Special Meeting, 17,987,408 public shares were tendered for redemption. After giving effect to the First Redemption, we had approximately $51.2 million remaining in the trust account.

On September 27, 2023, the Company, the Former Sponsor and the Sponsor entered into the Purchase Agreement. Pursuant to the Purchase Agreement, subject to satisfaction of certain conditions, the Sponsor (i) agreed to purchase an aggregate of 3,746,303 shares of Class B common stock from the Former Sponsor and each of the anchor investors and 4,160,000 Private Placement Warrants from the Former Sponsor for an aggregate purchase price of $16,288 and (ii) will become the Sponsor of the Company. In connection therewith, the Former Sponsor also entered into anchor transfer agreements with each of its anchor investors, whereby each anchor agreed, subject to the conditions contained therein, when and as directed by the Former Sponsor, to transfer 2/3 of their shares of Class B common stock for no consideration; provided, however, upon the request of an anchor investor, the Former Sponsor shall pay to them $0.0043 per share.

On October 6, 2023, (following approval by our stockholders at the October 2023 Special Meeting, we effected an amendment to our amended and restated certificate of incorporation, the effect of which was to (i) further extend the period of time by which we have to consummate an ~~Initial~~initial ~~Business~~business ~~Combination~~combination to July 31, 2024 and (ii) provide for the right of a holder of shares of Class B common stock to convert such shares into shares of Class A common stock on a one-to-one basis at any time and from time to time at the election of the holder. In connection with the October 2023 Special Meeting, 2,700,563 public shares were tendered for redemption and the Former Sponsor converted 3,000,000 of its shares of Class B common stock into shares of Class A common stock. Upon conversion of Class B common stock to Class A common stock, such Class A common stock will not be entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions. Immediately after giving effect to the Second Redemption and the Conversion, on October 24, 2023, we had approximately $24.3 million remaining in the Trust Account, and 5,312,029 shares of Class A common stock (including the 3,000,000 converted shares of Class B common stock) and 2,750,000 shares of Class B Common Stock outstanding.

In connection with the October 2023 Special Meeting, the Company, the Former Sponsor and the Sponsor entered into non-redemption agreements on substantially the same terms with certain stockholders of the Company, pursuant to which such stockholders agreed not to redeem (or to validly rescind any redemption requests on) an aggregate of 1,946,794 shares of Class A common stock in connection with the October 2023 Special Meeting. In exchange for the foregoing commitments not to redeem such shares of Class A common stock, the Sponsor agreed to transfer an aggregate of 389,359 shares of common stock held by the Sponsor to such stockholders immediately following consummation of an ~~Initial~~ ~~Business~~initial ~~Combination~~business combination.

On November 3, 2023, we entered into the Subscription Agreement with the Sponsor and Polar Multi-Strategy Master Fund, an unaffiliated third party, pursuant to which Polar agreed to make certain capital contributions to the Company of up to $1,200,000 from time to time, at the request of the Company, subject to the terms and conditions of the Subscription Agreement. Pursuant to the Subscription Agreement, the Capital Contribution shall be repaid to Polar by the Company within five (5) business days of the Company closing an Initial Business Combination. Polar may elect to receive such repayment (i) in cash or (ii) in shares of common stock of the surviving entity in such Initial Business Combination at a rate of one share of common stock for each ten dollars ($10.00) of the Capital Contribution that is funded. Additionally, in consideration of the Capital Contribution, at the closing of an Initial Business Combination, the Surviving Entity will issue to Polar one share of common stock for each dollar of Capital Contribution that is funded prior to the closing.28

On November 3, 2023, we entered into the Subscription Agreement with the Sponsor and Polar Multi-Strategy Master Fund, an unaffiliated third party, pursuant to which Polar agreed to make certain capital contributions to the Company of up to $1,200,000 from time to time, at the request of the Company, subject to the terms and conditions of the Subscription Agreement. Pursuant to the Subscription Agreement, the Capital Contribution shall be repaid to Polar by the Company within five (5) business days of the Company closing an initial business combination. Polar may elect to receive such repayment (i) in cash or (ii) in shares of common stock of the surviving entity in such initial business combination at a rate of one share of common stock for each ten dollars ($10.00) of the Capital Contribution that is funded. Additionally, in consideration of the Capital Contribution, at the closing of an initial business combination, the Surviving Entity will issue to Polar one share of common stock for each dollar of Capital Contribution that is funded prior to the closing.

On December 20, 2023, one of the Company’s anchor investors submitted 10,084 Class B common stock to the Company for no consideration to be cancelled.

In 2023, we engaged the services of multiple entities to act as capital market advisors, specifically to advise on market conditions, advise in connection with seeking an extension for completing an ~~Initial Business~~initial ~~Combination~~business combination, advise in connection with a possible ~~Initial~~initial ~~Business~~business ~~Combination~~combination, and acting as a placement agent in connection with a private placement of equity, equity-linked, convertible and/or debt securities or other capital or debt raising transaction. No fees are due the advisors until consummation of the ~~Initial~~initial ~~Business~~business ~~Combination~~combination and are payable at that time in a combination of cash and shares of common stock of the public company entity that survives the ~~Initial~~ ~~Business~~initial ~~Combination~~business combination. In accordance with ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) we have recognized a $418,400 liability at fair value for the shares to be issued upon consummation of the ~~Initial Business~~initial ~~Combination~~business combination. Additionally, we will pay $3,500,000 plus an amount equal to 4.0% (together the “Deferred CMA Fees”) of the sum of (A) the gross proceeds raised from investors identified by the advisor received by us or Target plus (B) proceeds released from the trust account in connection with the closing of the ~~Initial~~initial ~~Business~~business ~~Combination~~combination with respect to any stockholder of the Company that (x) entered into a non-redemption or other similar agreement or (y) did not redeem shares of the Company’s Class A common stock.

In accordance with ASC Topic 450, “Contingencies,” (“ASC 450”), the Company has not recognized a liability for the value of the potential issuance of shares or the Deferred CMA Fees since the completion of an ~~Initial~~ ~~Business~~initial ~~Combination~~business combination is a performance condition that is not yet considered probable.

On July 31, 2024, (following approval by our stockholders at the July 2024 Special Meeting, the Company effected an amendment to its amended and restated certificate of incorporation, the effect of which was to (i) further extend the period of time by which the Company has to consummate an ~~Initial~~initial ~~Business~~business ~~Combination~~combination to February 7, 2025 and to allow the Company, without the need for another stockholder vote, to elect to extend the Termination Date on a monthly basis for up to two times, by an additional one month each time, after February 7, 2025, by resolution of the Company’s board of directors if requested by the Sponsor, and upon five days’ advance notice prior to the applicable Termination Date and (ii) eliminate the limitation that the Company may not redeem public stock to the extent that such redemption would result in the Company having net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended), of less than $5,000,001 in order to allow the Company to redeem the Public Stock irrespective of whether such redemption would exceed the Redemption Limitation.

In connection with the July 2024 Special Meeting, the holders of 1,099,905 shares of Class A common stock properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.63 per share, for an aggregate redemption amount of $11,692,068. In addition, in connection with the July 2024 Special Meeting, the Sponsor and Former Sponsor converted an aggregate of 1,100,000 of their shares of Class B common stock into shares of Class A common stock on a one for one basis. Such converted shares of Class A common stock are not entitled to receive funds from the Trust Account through redemptions or otherwise and will remain subject to the existing transfer restrictions. After giving effect to the Third Redemption and the conversion, the Company had approximately $12.9 million remaining in the Trust Account, has 5,312,124 shares of Class A common stock (including 4,100,000 converted shares of Class B common stock) and 1,639,916 shares of Class B common stock outstanding.

In connection with the July 2024 Special Meeting, the Company and NewCo entered into non-redemption agreements (“2024 Non-Redemption Agreements”) with certain stockholders of the Company pursuant to which, such stockholders agreed not to redeem (or to validly rescind any redemption requests on) an aggregate of 1,047,399 shares of Class A common stock in connection with the July 2024 Special Meeting and to hold such shares through the July 2024 Special Meeting. In exchange for the foregoing commitments not to redeem such shares of Class A common stock, NewCo agreed to issue to such stockholders, for no additional consideration, an aggregate of 174,566 shares of Class A common stock of NewCo (and up to an aggregate of 232,750 shares of Class A common stock of NewCo if the Company utilizes the two monthly extensions described above), in connection with the consummation of the ~~Initial~~initial ~~Business~~business ~~Combination~~combination.

Additionally, the Company has utilized the two monthly extensions described above and extended the Combination Period to April 7, 2025. As a result, in connection with the consummation of the Business Combination, an aggregate of 232,750 share of NewCo Common Stock will be issued the stockholders that entered into the 2024 Non-Redemption Agreements.

Proposed Business Combination

On March 11, 2024, the Company entered into the Business Combination Agreement with NewCo, Merger Sub 1, Merger Sub 2, and XCF. Pursuant to the Business Combination Agreement, and subject to the terms and conditions contained therein, the Business Combination will be effected in two steps: (a) the Company will merge with and into Merger Sub 1, with Merger Sub 1 being the surviving entity of the NewCo Merger as a wholly owned subsidiary of NewCo; and (b) immediately following the NewCo Merger, Merger Sub 2 will merge with and into XCF, with XCF being the surviving corporation of the Company Merger as a wholly owned subsidiary of NewCo. As a result of the Business Combination, NewCo will become a new publicly-traded company.

On February 5, 2025, the SEC declared effective the registration statement on Form S-4, initially publicly filed by NewCo and XCF with the SEC on July 31, 2024. On February 27, 2025, the company’s stockholder approved at a special meeting the Business Combination Agreement and the transactions contemplated thereby. We expect to close the XCF Business Combination in the first half of 2025.

The Business Combination; Consideration

The Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, the following transactions will occur:

(i) the Company will merge with and into Merger Sub 1, with Merger Sub 1 being the surviving entity of the NewCo Merger as a direct wholly owned subsidiary of NewCo, and (x) each share of the Company’s Class A common stock, par value $0.0001 per share outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one share of NewCo’s Class A common stock, par value $0.0001 per share, (y) each share of the Company’s Class B common stock, par value $0.0001 per share, outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one share of NewCo Common Stock, and (z) each warrant of the Company outstanding immediately prior to the effectiveness of the NewCo Merger will be converted into the right to receive one warrant of NewCo, with NewCo assuming the Company’s rights and obligations under the existing warrant agreement; and

Table of Contents

Conditions to Closing

The Business Combination Agreement is subject to the satisfaction or waiver of certain customary closing conditions, including, among others, (a) approval of the Business Combination and related agreements and transactions by the Company’s stockholders and the XCF stockholders, (b) effectiveness of the Registration Statement to be filed by the Company and NewCo in connection with the Business Combination, (c) expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, (d) receipt of approval for listing on the NYSE or Nasdaq, as applicable, the shares of NewCo Common Stock to be issued in connection with the Business Combination, and (e) the absence of any order, law or other legal restraint or prohibition preventing the consummation of the Business Combination in effect. Other conditions to XCF’s obligations to consummate the Business Combination include, among others, (i) the accuracy of the representations and warranties of the Company as of the Closing, (ii) the performance or compliance of each of the Company’s covenants in all material respects at or prior to the Closing and (iii) receipt of a certificate signed by an authorized officer of the Company certifying the satisfaction of the preceding clauses (i) and (ii). Other conditions to the Company’s obligations to consummate the Business Combination include, among others, (v) closing of the acquisition of New Rise Renewables, LLC and New Rise SAF Renewables Limited Liability Company, (w) entry into an amended and restated supply and offtake agreement with a key supplier or another party on terms and conditions reasonably satisfactory to the Company, (x) the accuracy of the representations and warranties of XCF as of the Closing, (y) the performance or compliance of each XCF covenant in all material respects at or prior to the Closing and (z) receipt of a certificate signed by an XCF authorized officer certifying the satisfaction of the preceding clauses (x) and (y).

Covenants

Representations and Warranties

Termination

The Business Combination Agreement contains certain termination rights for both the Company and XCF including, among others, that the Business Combination Agreement may be terminated at any time prior to the Closing (i) by mutual written consent of the Company and XCF, (ii) by written notice from either the Company or XCF to the other if certain approvals of the Company’s stockholders, to the extent required under the Business Combination Agreement, are not obtained as set forth therein, (iii) by written notice from the Company, if certain approvals of the XCF stockholders are not obtained within two (2) business days after the Registration Statement is declared effective, (iv) by written notice from the Company if the Key Agreement is not entered into by a specified date or a key supplier exercises certain rights under the Key Agreement in connection with the Business Combination and (v) by either the Company or XCF in certain other circumstances set forth in the Business Combination Agreement, including, among others, (a) if the Closing is permanently enjoined, restrained or prohibited by the terms of a final, non-appealable governmental order, (b) in the event of certain uncured breaches by the other party, (c) if the Company’s stockholders do not approve the Business Combination or (d) if the Closing has not occurred on or prior to September 11, 2024, provided that such date will be automatically extended to November 11, 2024 if the Registration Statement is not declared effective on or prior to September 11, 2024.

Reimbursable Expenses

1) any expenses payable to any governmental authority in connection with the Business Combination Agreement, including the Hart-Scott-Rodino Act filing fee and the S-4 filing fee; 2) registrar, transfer agent and printer expenses; 3) fees and expenses of third party advisors; 4) fees and expenses of auditors and accountants; 5) excise taxes of the Company; and 6) any placement fee and any other fees, costs or expenses incurred in connection with NewCo’s listing on the Applicable Exchange.

2) registrar, transfer agent and printer expenses;

3) fees and expenses of third party advisors;

4) fees and expenses of auditors and accountants;

5) excise taxes of the Company; and

6) any placement fee and any other fees, costs or expenses incurred in connection with NewCo’s listing on the Applicable Exchange.

Amendment No. 1 to the Business Combination Agreement

Amendment No. 2 to the Business Combination Agreement

Certain Related Agreements

Sponsor Letter Agreement

On March 11, 2024, concurrently with the execution and delivery of the Business Combination Agreement, the Company entered into the Sponsor Letter Agreement, with the Sponsor and NewCo, pursuant to which the Sponsor has unconditionally and irrevocably agreed to, among other things: (a) vote at any meeting of the stockholders of the Company, and in any action by written resolution of the stockholders of the Company, all of the shares of the Company’s Class B common stock held by the Sponsor to approve the Business Combination and all related transactions and proposals; (b) vote against any proposal, action or agreement that would result in a breach of any of the Company’s covenants, representations, warranties or other obligations or agreements under the Business Combination Agreement; and (c) waive any rights to adjustment or other anti-dilution or similar protections with respect to the rate at which the shares of the Company’s Class B common stock held by the sponsor will convert into other shares of capital stock of the Company or shares of NewCo Common Stock in connection with the Business Combination and related transactions; in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement.

Table of Contents

Support Agreements

On March 11, 2024, concurrently with the execution and delivery of the Business Combination Agreement, the Company, NewCo and XCF entered into the Support Agreements with (i) Randy Soule, majority stakeholder of New Rise, and his affiliated entity, (ii) GL Part SPV I, LLC, an existing XCF stockholder and New Rise equityholder, (iii) certain XCF stockholders and (iv) certain members of XCF management. Pursuant to the Support Agreements, certain XCF stockholders and New Rise equityholders agreed to, among other things, vote to adopt and approve the Business Combination Agreement and all other documents and transactions contemplated thereby, in each case, subject to the terms and conditions of the Support Agreements, and vote against any alternative transaction, business combination or agreement that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, adversely affect or prevent the Closing of the Business Combination or the Support Agreements or result in a breach of any covenant, representation, warranty or any other obligation or agreement thereunder.

Pursuant to the Support Agreements:

(ii) each of the XCF stockholders party to the Company Support Agreements and the party to the GL Support Agreement have also agreed that with respect to 90% of shares of NewCo Common Stock held by such parties, they will not transfer such Lock-up Shares until the earlier of (x) twelve months after the Closing and (y) the date on which NewCo (or its successor) completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of NewCo’s (or such successor’s) stockholders having the right to exchange their securities for cash, securities or other property; provided that such transfer restrictions will lapse prior to their expiration upon the occurrence of certain events, including the closing price of the shares of NewCo Common Stock equaling or exceeding $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing at least 150 days after the Closing; provided, further, that such parties may transfer (A) on or after 90 days following the first quarterly earnings release published following the Closing, 10% of the Lock-up Shares, (B) on or after 180 days following the closing date of the Business Combination, 30% of the Lock-up Shares and (C) on or after 360 days following the closing date of the Business Combination, 60% of the Lock-up Shares; and

(iii) the Soule Support Agreement does not contain any lock-up restrictions following the Closing.

Convertible Promissory Note

On February 26, 2024, the Company issued an unsecured promissory note in the total principal amount of up to $500,000 (the “FI Sponsor Promissory Note”) to the Sponsor. The FI Sponsor Promissory Note does not bear interest and matures upon closing of the Company’s ~~Initial~~initial ~~Business~~business ~~Combination~~combination. In the event that the Company does not consummate an ~~Initial~~initial ~~Business~~business ~~Combination~~combination, the FI Sponsor Promissory Note will be repaid only from amounts remaining outside of the Trust Account. Up to the total principal amount of the FI Sponsor Promissory Note may be converted, in whole or in part, at the option of the lender into warrants of the Company at a price of $1.50 per warrant, which warrants will be identical to the Private Placement Warrants issued to the Former Sponsor at the time of the initial public offering of the Company. At ~~September~~March 3031, 2025 and December 31, 2024, $110,000 was drawn on the note.

Securities Listing

Uncertain Tax Position

We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Our operations included those activities necessary to consummate an ~~Initial~~initial ~~Business~~business ~~Combination~~combination. As such, we deducted startup and operating costs for tax purposes. Additionally, the Company has taken the position that no income should the apportioned to Florida in its Florida state tax return. As there is uncertainty in the deduction of startup and operating costs and the apportionment of income to the State of Florida, the Company recognized a reserve for uncertain tax positions on the balance sheet in 2023. In 2024, the Company reversed its position related to the deductibility of start-up and operating costs for tax purposes and no longer reports an uncertain tax position for these items. The Company continues to take the position that no income should the apportioned to Florida in its Florida state tax return. As such, the Company maintains an uncertain tax position related to its Florida tax return. At ~~September~~March 3031, ~~2024~~2025 and December 31, ~~2023,~~2024 the Company reported $115,870 ~~and $955,617, respectively,~~ on the consolidated condensed balance ~~sheet~~sheets for ~~these~~this uncertainty.

Results of Operations

Our entire activity from inception up to October 7, 2021 was in preparation for our initial public offering and, since the consummation of our initial public offering, the search for and ~~consumption~~consummation of a prospective target business. We will not generate any operating revenues until the closing and completion of our Initial Business Combination, at the earliest.

30 For the three months ended March 31, 2025, we had a net loss of $1,426,442 which primarily consisted of $1,295,159 in operating costs, $15,744 in excise tax interest and penalties, $216,953 of change in fair value of Note Payable – Polar and $51,986 in income tax expenses, partially offset by Trust Account interest income of $143,400 and $10,000 from change in fair value of 2024 Non-redemption Agreement.

For the three months ended March 31, 2024, we had net loss of $2,504,756, which primarily consisted of a loss of $95,986 from a change in fair value of Note Payable – Polar, interest income of $320,299, an income tax expense of $84,004 and $2,646,244 in operating costs, partially offset by operating account interest income of $1,179 and trust interest income of $320,299.

For the three months ended September 30, 2024, we had a net loss of $1,006,971 which primarily consisted of $1,047,765 in operating costs (net of $174,232 of Reimbursable Expenses), and $920,000 of change in fair value of the 2024 Non-Redemption Agreements, partially offset by operating account interest income of $719, gain of $716,000 from a change in fair valuation of derivative warrant liabilities, a gain of $13,745 from a change in fair value of Note Payable – Polar, Trust Account interest income of $230,142 and an income tax benefit of $188.

For the three months ended September 30, 2023, we had a net loss of $701,173, which primarily consisted of a loss of $56,185 from a change in fair value of convertible promissory note, an income tax expense of $645,032, loss of $524,470 from a change in fair valuation of derivative warrant liabilities and $185,297 in operating costs, partially offset by Trust Account interest income of $709,811.

For the nine months ended September 30, 2024, we had a net loss of $4,960,533, which primarily consisted of a loss of $96,577 from a change in fair value of Note Payable – Polar, an income tax expense of $114,461, $5,064,404 in operating costs (net of $174,232 of Reimbursable Expenses), and $920,000 of change in fair value of the 2024 Non-Redemption Agreements, partially offset by operating account interest income of $3,374, gain of $358,000 from a change in fair valuation of derivative warrant liabilities and Trust Account interest income of $873,535.

For the nine months ended September 30, 2023, we had a net income of $1,782,882, which consisted of Trust Account interest income of $1,874,489, a gain of $360,789 from a change in fair valuation of convertible promissory note, and a gain of $1,226,150 from a change in fair valuation of derivative warrant liabilities, offset by $788,932 in operating costs and an additional $889,614 in provision for income taxes.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred and expect to continue to incur additional costs in pursuit of our ~~Initial~~initial ~~Business~~business ~~Combination~~combination. We have determined that we will not be able to sustain operations for the next twelve months without additional financing. As of ~~September~~March 3031, ~~2024~~2025, we had $~~594~~22,~~619~~604 in our operating bank account available for working capital needs and a working capital deficit of $69,~~982~~597,~~150~~976.

Until the consummation of the Initial Public Offering, the Company’s liquidity needs have been satisfied through a payment of $25,000 from the Former Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the founder shares (as defined in Note 3) and a Note Payable to Former Sponsor (Note 3) in the amount of $563,009 that was fully repaid on October 7, 2021.

In association with the Subscription Agreement (discussed in Note 3), the Company has borrowed $1,200,000.

On February 26, 2024, the Company issued the FI Sponsor Promissory Note to the Sponsor in the total principal amount of up to $500,000 and had borrowed $110,000 under the FI Sponsor Promissory Note at ~~September~~ 30March 31, 2025 and December 31, 2024.

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that ~~the~~its ~~mandatory~~inability ~~liquidation~~to ~~and~~satisfy ~~subsequent~~its ~~dissolution,~~working ~~should~~capital ~~the~~obligations ~~Company~~as beof ~~unable~~the toexpected ~~complete~~mandatory anliquidation ~~Initial~~date ~~Business~~and ~~Combination,~~subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The Company has until ~~February~~October 7, 2025 (as ~~may be~~ extended ~~until~~by ~~April~~the 7,board ~~2025~~of directors), to consummate an ~~Initial~~initial ~~Business~~business ~~Combination~~combination, which would provide the Company with the ability to satisfy its working capital obligations. ItHowever, it is uncertain that the Company will be able to consummate an ~~Initial Business~~initial ~~Combination~~business combination by this time. If an ~~Initial~~initial ~~Business~~business ~~Combination~~combination is not consummated by this date, and the Termination Date is not extended beyond ~~April~~October 7, 2025, there will be a mandatory liquidation and subsequent dissolution. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after ~~February~~October 7, 2025 ~~(as may be extended until April 7, 2025)~~.

To alleviate the Company’s assessment of going concern, on March 11, 2024, the Company entered into a proposed Business Combination Agreement with XCF.

Contractual Obligations

Registration Rights

The holders of the founder shares, private placement warrants and warrants that may be issued upon conversion of working capital loans (and any Class A common stock issuable upon the exercise of the private placement warrants and warrants that may be issued upon conversion of working capital loans) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the initial public offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of our ~~Initial~~initial ~~Business~~business ~~Combination~~combination.

However, the registration rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the founder shares, as described in the following paragraph, and (ii) in the case of the private placement warrants and the respective shares of our Class A common stock underlying such warrants, 30 days after the completion of our ~~Initial~~initial ~~Business~~business ~~Combination~~combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Except as described in this ~~Quarterly~~Annual Report, the holders of the founder shares (including the anchor investors) have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of (a) one year after the completion of our initial ~~Business~~business ~~Combination~~combination, or (b) subsequent to our ~~Initial~~initial ~~Business~~business ~~Combination~~combination, (x) if the last reported sale price of our Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our ~~Initial~~initial ~~Business~~business ~~Combination~~combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange or other similar transaction that results in all of our public stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of our Sponsor with respect to any founder shares.

In addition, pursuant to the registration rights agreement, our Sponsor, upon completion of an Initial Business Combination, will be entitled to nominate up to three individuals for election to our board of directors, as long as the Sponsor holds any securities covered by the registration rights agreement.34

In addition, pursuant to the registration rights agreement, our Sponsor, upon completion of an initial business combination, will be entitled to nominate up to three individuals for election to our board of directors, as long as the Sponsor holds any securities covered by the registration rights agreement.

Underwriting Agreement

The underwriters were paid a cash underwriting discount of 2.0% of the gross proceeds of the initial public offering, or $4.6 million. In addition, the underwriters were entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the Initial Public Offering, or $8,050,000. As a result, $7,548,450 of the deferred underwriters’ fee was reversed through equity as it related to the Redeemable Class A common stock issued in the initial public offering and $501,550 of the deferred underwriters’ fee was reversed through the statement of operations as it related to the public warrants issued in the initial public offering.

Capital Market Advisors

In 2023, the Company engaged the services of multiple entities to act as capital market advisors, specifically to advise on market conditions, advise in connection with seeking an extension for completing an ~~Initial~~initial ~~Business~~business ~~Combination~~combination, advise in connection with a possible ~~Initial~~initial ~~Business~~business ~~Combination~~combination, and acting as a placement agent in connection with a private placement of equity, equity-linked, convertible and/or debt securities or other capital or debt raising transaction. No fees are due the advisors until consummation of the ~~Initial~~initial ~~Business~~business ~~Combination~~combination and are payable at that time in a combination of cash and shares of common stock of the public company entity that survives the ~~Initial~~initial ~~Business~~business ~~Combination~~combination. In accordance with ASC 718, at the effective date of November 2, 2023, the value of the shares issuable as of the execution date of the contracts was $312,600. Additionally, the Company will pay $3,500,000 plus an amount equal to 4.0% (together the “Deferred CMA Fees”) of the sum of (A) the gross proceeds raised from investors identified by the advisor received by the Company or Target plus (B) proceeds released from the Trust Account in connection with the closing of the ~~Initial~~initial ~~Business~~business ~~Combination~~combination with respect to any stockholder of the Company that (x) entered into a non-redemption or other similar agreement or (y) did not redeem shares of the Company’s Class A common stock.

In accordance with ASC Topic 450, “Contingencies,” (“ASC 450”), the Company has not recognized a liability for the value of the potential issuance of shares or the Deferred CMA Fees since the completion of an ~~Initial~~initial ~~Business~~business ~~Combination~~combination is a performance condition that is not yet considered probable.

Critical Accounting Estimates

The preparation of ~~unaudited~~condensed consolidated ~~condensed~~ financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the ~~unaudited~~condensed consolidated ~~condensed~~ financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Note Payable - Polar

We report the Note Payable – Polar at fair value using a bond plus call plus model. Included in the model are significant estimates and judgment about inputs into the model. Deviations from these estimates could result in a significant difference to our financial results.

Share Subscription Agreement - Polar

The share subscription agreement is reported based on the residual value of the Subscription Agreement and was determined based on the residual amount of the proceeds received less the fair value of the Note Payable – Polar. Deviations from the estimated fair value of the Note Payable – Polar could result in a significant difference to our financial results.

2024 Non-Redemption Agreements

The 2024 Non-Redemption Agreements is reported at fair value using a likelihood-weighted scenario analysis model. The model uses significant judgment and estimates as inputs in the model. Deviations from the estimated fair value of the 2024 Non-Redemption Agreements could result in a significant difference to our financial results.

Recent Accounting Pronouncements

Our management does not believe that there are any recently issued, but not yet effective, accounting pronouncements, if currently adopted, that would have a material effect on our ~~unaudited~~condensed consolidated ~~condensed~~ financial statements.

Off-Balance Sheet Arrangements

As of ~~September~~March 3031, ~~2024~~2025, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

JOBS Act

The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until we are no longer an “emerging growth company,” whichever is earlier.

3236

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. ~~Controls and Procedures~~

Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our principle executive officer and principle financial officer, to allow timely decisions regarding required disclosure. As required by Rules 13a-15 and 15d-15 under the Exchange Act, our principle executive officer and principle financial officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of ~~September~~March 3031, ~~2024~~2025. Based upon their evaluation, our principle executive officer and principle financial officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective due to material weakness in our internal controls over financial reporting of complex financial instruments and the failure to properly design the financial closing and reporting process to record, review and monitor compliance with generally accepted accounting principles for transactions on a timely basis.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3337

PART II—OTHER

INFORMATION

Item 1. ~~Legal Proceedings~~

Legal Proceedings

There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team.

Item 1A. ~~Risk Factors~~

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K for the year ended December 31, 2023, ~~filed~~ Risk with the SEC on April 23, 2024 (the “Annual Report”). Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known toFactors us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report, except for the below risk factor. We may disclose changes to such risk factor or disclose additional risk factor from time to time in our future filings with the SEC.

~~Nasdaq~~ Factors ~~has~~that ~~delisted~~could cause our ~~securities~~actual results to differ materially from ~~trading~~those in this Quarterly Report are any of the risks described in our Annual Report on ~~its~~Form ~~exchange~~10-K for the year ended December 31, ~~which~~2024, ~~could~~filed ~~limit~~with ~~investors’ ability~~the toSEC ~~make~~on ~~transactions~~March 26, 2025 (the “Annual Report”). Any of these factors could result in a significant or material adverse effect on our ~~securities~~results ~~and~~of ~~subject~~operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to ~~additional~~the ~~trading~~risk ~~restrictions~~factors disclosed in our Annual Report.

~~On October 7, 2024, the Company received the Delisting Notice from the staff of the Listing Qualifications Department of Nasdaq stating~~ ~~that~~ Item Nasdaq has determined to delist the Company’s securities from The Nasdaq Capital Market and will suspend trading in those securities effective at the open of business on October 14, 2024. Nasdaq reached its decision pursuant to Nasdaq IM-5101-2 ~~because the Company did not complete one or more business combinations within 36 months of the effectiveness of its Initial Public Offering registration statement~~.

~~Following~~ Unregistered ~~the~~Sales ~~suspension~~ of ~~trading~~Equity onSecurities ~~Nasdaq,~~and ~~the~~Use ~~Company’s Units, shares~~ of ~~Class~~ ~~A common stock and redeemable warrants trade on the OTC Pink Marketplace under the symbols “BHACU,” “BHAC” and “BHACW,” respectively~~Proceeds. ~~As a result, we may face significant material adverse consequences, including:~~

• reduced liquidity for our securities;

• a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules, including being subject to the depository requirements of Rule 419 of the Securities Act, and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

• a limited amount of news and analyst coverage with respect to our securities; and

• a decreased ability to issue additional securities or obtain additional financing in the future.

Additionally, the National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” Because our securities were delisted from Nasdaq, our Units, Class A common stock and warrants do not qualify as covered securities under under the Securities Act and we are subject to regulation in each state in which we offer our securities.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Not Applicable.

Item 3. ~~Defaults upon Senior Securities~~

Defaults upon Senior Securities

None.

Item 4. ~~Mine Safety Disclosures.~~

Mine Safety Disclosures.

Not applicable.

Item 5. ~~Other Information.~~

~~During the quarter ended September 30, 2024, none of our directors or executive officers~~ ~~adopted~~ Other or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as such term is defined in Item 408(a) of Regulation S-KInformation.

34 During the quarter ended March 31, 2025, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as such term is defined in Item 408(a) of Regulation S-K.

Item 6.

Exhibits.

Exhibit Number	Description	~~Description~~
2.1(1)	Business Combination Agreement, dated as of March 11, 2024.	~~Business Combination Agreement, dated as of March 11, 2024.~~
2.2		Amendment No. 1 to Business Combination Agreement, dated as of November 29, 2024.
2.2(4)	Amendment No. 1 to Business Combination Agreement, dated as of November 29, 2024.
3.1(2)		Amendment to Amended and Restated Certificate of Incorporation, dated July 31, 2024 (Extension Amendment).
2.3(5)	Amendment No. 2 to Business Combination Agreement, dated as of April 4, 2025.
3.2(2)		Amendment to Amended and Restated Certificate of Incorporation, dated July 31, 2024 (Redemption Limitation Amendment).
3.1(2)	Amendment to Amended and Restated Certificate of Incorporation, dated July 31, 2024 (Extension Amendment).
10.1(3)		Promissory Note, dated February 26, 2024, by and between Focus Impact BH3 Acquisition Company and Focus Impact BHAC Sponsor, LLC.
3.2(2)	Amendment to Amended and Restated Certificate of Incorporation, dated July 31, 2024 (Redemption Limitation Amendment).
10.2(1)		Sponsor Letter Agreement, dated as of March 11, 2024.
3.3(6)	Amendment to Amended and Restated Certificate of Incorporation, dated April 7, 2025 (Extension Amendment).
10.3(1)		Soule Support Agreement, dated as of March 11, 2024.
10.1(3)	Promissory Note, dated February 26, 2024, by and between Focus Impact BH3 Acquisition Company and Focus Impact BHAC Sponsor, LLC.
10.4(1)		GL Support Agreement, dated as of March 11, 2024.
10.2(1)	Sponsor Letter Agreement, dated as of March 11, 2024.
10.5(1)		Form of Company Support Agreement.
10.3(1)	Soule Support Agreement, dated as of March 11, 2024.
10.6(1)		Form of Management Support Agreement.
10.4(1)	GL Support Agreement, dated as of March 11, 2024.
31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
10.5(1)	Form of Company Support Agreement.
31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
10.6(1)	Form of Management Support Agreement.
32.1**		Certification of Chief Executive Officer (Principal Executive Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document
32.1**	Certification of Chief Executive Officer (Principal Executive Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
32.2**	Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.INS*	Inline XBRL Instance Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.


*	Filed herewith.
**	These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
(1)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on March 12, 2024.
(2)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on August 6, 2024.
(3)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on March 1, 2024.
(4)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on December 5, 2024.
(5)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on April 7, 2025.
(6)	Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on April 11, 2025.

** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.39

(1) Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on March 12, 2024.

(2) Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on August 6, 2024.

(3) Incorporated by reference to an exhibit to our Current Report on Form 8-K filed with the SEC on March 1, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this ~~11th~~23rd day of ~~December~~ May, ~~2024~~2025.


FOCUS IMPACT BH3 ACQUISITION COMPANY

By:	/s/ Carl Stanton
Name:	Carl Stanton
Title:	Chief Executive Officer (Principal Executive Officer)


By:	/s/ Ernest Lyles
Name:	Ernest Lyles
Title:	Chief Financial Officer
	(Principal Financial and Accounting Officer)

36 40

NONE NONE NONE http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent P1M 1 0.5 0.67 http://fasb.org/us-gaap/2024#InvestorMember 1 http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants P1M 0001851612 false Q1 --12-31 0001851612 2025-01-01 2025-03-31 0001851612 bhac:PublicSharesMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassAMember 2025-01-01 2025-03-31 0001851612 bhac:RedeemableWarrantsMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassAMember 2025-05-23 0001851612 us-gaap:CommonClassBMember 2025-05-23 0001851612 2025-03-31 0001851612 2024-12-31 0001851612 us-gaap:RelatedPartyMember 2025-03-31 0001851612 us-gaap:RelatedPartyMember 2024-12-31 0001851612 us-gaap:CommonClassAMember 2025-03-31 0001851612 us-gaap:CommonClassAMember 2024-12-31 0001851612 us-gaap:CommonClassBMember 2025-03-31 0001851612 us-gaap:CommonClassBMember 2024-12-31 0001851612 2024-01-01 2024-03-31 0001851612 us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001851612 bhac:CommonClassANonredeemableMember 2025-01-01 2025-03-31 0001851612 bhac:CommonClassANonredeemableMember 2024-01-01 2024-03-31 0001851612 us-gaap:CommonClassBMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassBMember 2024-01-01 2024-03-31 0001851612 us-gaap:PreferredStockMember 2024-12-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0001851612 us-gaap:RetainedEarningsMember 2024-12-31 0001851612 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001851612 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001851612 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001851612 us-gaap:PreferredStockMember 2025-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-03-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-03-31 0001851612 us-gaap:RetainedEarningsMember 2025-03-31 0001851612 us-gaap:PreferredStockMember 2023-12-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001851612 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001851612 us-gaap:RetainedEarningsMember 2023-12-31 0001851612 2023-12-31 0001851612 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001851612 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001851612 us-gaap:PreferredStockMember 2024-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001851612 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001851612 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001851612 us-gaap:RetainedEarningsMember 2024-03-31 0001851612 2024-03-31 0001851612 srt:MinimumMember 2021-02-23 2021-02-23 0001851612 us-gaap:IPOMember 2021-10-04 2021-10-04 0001851612 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-04 0001851612 bhac:PublicWarrantsMember us-gaap:IPOMember 2021-10-04 0001851612 bhac:PublicWarrantsMember us-gaap:CommonClassAMember 2021-10-04 0001851612 bhac:PublicWarrantsMember us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-04 0001851612 bhac:PrivatePlacementWarrantsMember 2021-10-07 2021-10-07 0001851612 bhac:PrivatePlacementWarrantsMember 2021-10-07 0001851612 us-gaap:IPOMember 2021-10-07 2021-10-07 0001851612 bhac:PrivatePlacementWarrantsMember us-gaap:IPOMember 2021-10-07 0001851612 srt:MinimumMember 2025-03-31 0001851612 srt:MinimumMember 2025-01-01 2025-03-31 0001851612 srt:MaximumMember 2025-03-31 0001851612 bhac:PublicSharesMember 2025-03-31 0001851612 us-gaap:CommonClassAMember 2022-12-07 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember bhac:PurchaseAgreementMember 2023-09-27 0001851612 bhac:PrivatePlacementWarrantsMember us-gaap:InvestorMember bhac:PurchaseAgreementMember 2023-09-27 0001851612 bhac:PrivatePlacementWarrantsMember bhac:PurchaseAgreementMember 2023-09-27 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember bhac:PurchaseAgreementMember 2023-09-27 2023-09-27 0001851612 2023-10-06 2023-10-06 0001851612 us-gaap:CommonClassBMember 2023-10-06 2023-10-06 0001851612 us-gaap:CommonClassBMember 2023-10-24 0001851612 us-gaap:CommonClassAMember 2023-10-24 0001851612 us-gaap:CommonClassBMember 2023-10-24 2023-10-24 0001851612 us-gaap:CommonClassAMember 2023-10-06 0001851612 2023-10-06 0001851612 bhac:PolarMultiStrategyMasterFundMember 2023-11-03 0001851612 bhac:PolarMultiStrategyMasterFundMember 2025-01-01 2025-03-31 0001851612 bhac:PolarMultiStrategyMasterFundMember 2023-11-03 2023-11-03 0001851612 us-gaap:CommonClassBMember 2023-12-20 2023-12-20 0001851612 srt:MaximumMember 2024-07-31 2024-07-31 0001851612 srt:MinimumMember 2024-07-31 0001851612 us-gaap:CommonClassAMember 2024-07-31 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-07-31 2024-07-31 0001851612 2024-07-01 2024-07-31 0001851612 us-gaap:CommonClassBMember 2024-07-31 0001851612 us-gaap:CommonClassBMember 2024-07-31 2024-07-31 0001851612 bhac:FocusImpactBH3NewcoIncMember us-gaap:CommonClassAMember 2024-07-31 0001851612 bhac:FocusImpactBH3NewcoIncMember 2024-07-31 2024-07-31 0001851612 us-gaap:CommonClassBMember 2024-12-17 2024-12-17 0001851612 us-gaap:CommonClassAMember 2024-12-17 0001851612 us-gaap:CommonClassAMember 2024-12-17 2024-12-17 0001851612 us-gaap:CommonClassBMember 2024-12-17 0001851612 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2025-04-07 0001851612 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001851612 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2025-04-07 0001851612 bhac:FocusImpactBH3MergerSubILLCMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2024-03-11 2024-03-11 0001851612 bhac:FocusImpactBH3MergerSubILLCMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2024-03-11 0001851612 bhac:FocusImpactBH3MergerSubILLCMember us-gaap:InvestorMember 2024-03-11 2024-03-11 0001851612 bhac:FocusImpactBH3MergerSubIIIncMember bhac:XCFGlobalCapitalIncMember 2024-03-11 0001851612 bhac:FocusImpactBH3MergerSubIIIncMember bhac:XCFGlobalCapitalIncMember 2025-01-01 2025-03-31 0001851612 us-gaap:InvestorMember us-gaap:CommonClassAMember bhac:SponsorLetterAgreementMember 2025-01-01 2025-03-31 0001851612 srt:MinimumMember us-gaap:InvestorMember bhac:SponsorLetterAgreementMember 2024-03-11 0001851612 srt:MinimumMember bhac:SupportAgreementsMember 2024-03-11 0001851612 bhac:SouleSupportAgreementMember 2024-03-11 2024-03-11 0001851612 bhac:SouleSupportAgreementMember 2024-03-11 0001851612 bhac:GLSupportAgreementMember 2024-03-11 0001851612 bhac:XCFGlobalCapitalIncMember bhac:ManagementSupportAgreementMember 2025-01-01 2025-03-31 0001851612 bhac:XCFGlobalCapitalIncMember bhac:ManagementSupportAgreementMember 2024-03-11 0001851612 bhac:GLSupportAgreementMember 2024-03-11 2024-03-11 0001851612 bhac:XCFGlobalCapitalIncMember bhac:GLSupportAgreementMember 2024-03-11 0001851612 bhac:XCFGlobalCapitalIncMember bhac:GLSupportAgreementMember 2025-01-01 2025-03-31 0001851612 bhac:GLSupportAgreementMember 2025-01-01 2025-03-31 0001851612 bhac:PromissoryNoteMember 2025-01-01 2025-03-31 0001851612 bhac:PromissoryNoteMember 2025-03-31 0001851612 bhac:PromissoryNoteMember 2023-07-31 0001851612 bhac:NotePayablePolarMember 2025-01-01 2025-03-31 0001851612 srt:MaximumMember bhac:ConvertiblePromissoryNotesMember bhac:SponsorMember 2024-02-26 0001851612 bhac:ConvertiblePromissoryNotesMember bhac:SponsorMember 2025-01-01 2025-03-31 0001851612 bhac:XCFGlobalCapitalIncMember 2025-01-01 2025-03-31 0001851612 bhac:XCFGlobalCapitalIncMember 2024-01-01 2024-12-31 0001851612 2023-11-02 0001851612 2023-11-02 2023-11-02 0001851612 bhac:PromissoryNoteMember us-gaap:InvestorMember 2024-02-26 0001851612 bhac:PromissoryNoteMember us-gaap:InvestorMember 2023-07-31 0001851612 2023-07-31 0001851612 us-gaap:CommonClassBMember 2023-10-06 0001851612 bhac:NotePayablePolarMember 2024-01-01 2024-12-31 0001851612 bhac:NotePayablePolarMember 2025-03-31 0001851612 bhac:NotePayablePolarMember 2024-12-31 0001851612 bhac:NotePayablePolarMember 2024-01-01 2024-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:IPOMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassAMember us-gaap:IPOMember 2025-03-31 0001851612 2025-02-28 0001851612 us-gaap:WarrantMember us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001851612 us-gaap:WarrantMember us-gaap:CommonClassAMember 2025-01-01 2025-03-31 0001851612 bhac:CommonClassAAndClassBMember 2025-01-01 2025-03-31 0001851612 bhac:CommonClassAAndClassBMember 2024-01-01 2024-03-31 0001851612 bhac:FounderSharesMember us-gaap:CommonClassBMember 2021-10-07 2021-10-07 0001851612 bhac:FounderSharesMember us-gaap:CommonClassBMember 2021-10-07 0001851612 bhac:FounderSharesMember 2021-10-07 2021-10-07 0001851612 bhac:FounderSharesMember 2021-10-07 0001851612 bhac:FounderSharesMember 2025-03-31 0001851612 bhac:FounderSharesMember us-gaap:IPOMember 2021-10-06 2021-10-06 0001851612 srt:MaximumMember bhac:FounderSharesMember us-gaap:IPOMember 2021-10-06 0001851612 bhac:FounderSharesMember us-gaap:InvestorMember 2021-10-06 2021-10-06 0001851612 bhac:FounderSharesMember us-gaap:InvestorMember 2021-10-06 0001851612 bhac:FounderSharesMember us-gaap:CommonClassAMember 2025-03-31 0001851612 bhac:FounderSharesMember us-gaap:CommonClassAMember 2025-01-01 2025-03-31 0001851612 srt:MinimumMember bhac:FounderSharesMember us-gaap:CommonClassAMember 2025-03-31 0001851612 bhac:FounderSharesMember 2025-01-01 2025-03-31 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2023-11-02 0001851612 bhac:PrivatePlacementWarrantsMember us-gaap:InvestorMember 2023-11-02 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2023-11-02 2023-11-02 0001851612 us-gaap:CommonClassBMember 2023-11-02 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2023-10-31 2023-10-31 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-07-01 2024-07-31 0001851612 bhac:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember 2021-10-07 0001851612 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-10-07 0001851612 bhac:PrivatePlacementWarrantsMember 2025-01-01 2025-03-31 0001851612 bhac:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2022-11-01 0001851612 us-gaap:InvestorMember 2022-11-01 0001851612 bhac:ConvertiblePromissoryNotesMember us-gaap:InvestorMember 2024-02-26 0001851612 us-gaap:InvestorMember us-gaap:CommonClassBMember 2023-10-01 2023-10-31 0001851612 bhac:PublicWarrantsMember 2025-03-31 0001851612 bhac:PrivatePlacementWarrantsMember 2024-12-31 0001851612 srt:MinimumMember bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember us-gaap:CommonClassAMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember 2025-01-01 2025-03-31 0001851612 srt:MinimumMember bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember us-gaap:CommonClassAMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember 2025-01-01 2025-03-31 0001851612 srt:MaximumMember us-gaap:CommonClassAMember bhac:AdditionalOfferingMember 2025-03-31 0001851612 srt:MinimumMember bhac:AdditionalOfferingMember 2025-01-01 2025-03-31 0001851612 bhac:AdditionalOfferingMember 2025-01-01 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember bhac:AdditionalOfferingMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember bhac:AdditionalOfferingMember 2025-03-31 0001851612 bhac:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember us-gaap:CommonClassAMember bhac:AdditionalOfferingMember 2025-01-01 2025-03-31 0001851612 us-gaap:CommonClassAMember 2023-12-31 0001851612 us-gaap:CommonClassAMember 2024-01-01 2024-12-31 0001851612 srt:MaximumMember bhac:PromissoryNoteMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 us-gaap:FairValueInputsLevel1Member bhac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel1Member bhac:PublicWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 us-gaap:FairValueInputsLevel2Member bhac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel2Member bhac:PrivatePlacementWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:EmbeddedDerivativeOnWorkingCapitalLoansMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:EmbeddedDerivativeOnWorkingCapitalLoansMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:NotePayablePolarMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:NotePayablePolarMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:NonRedemptionAgreementsMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001851612 us-gaap:FairValueInputsLevel3Member bhac:NonRedemptionAgreementsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001851612 bhac:NonRedemptionAgreementsMember 2024-12-31 0001851612 bhac:WorkingCapitalLoanConversionOptionMember 2024-12-31 0001851612 bhac:NonRedemptionAgreementsMember 2025-01-01 2025-03-31 0001851612 bhac:WorkingCapitalLoanConversionOptionMember 2025-01-01 2025-03-31 0001851612 bhac:NonRedemptionAgreementsMember 2025-03-31 0001851612 bhac:WorkingCapitalLoanConversionOptionMember 2025-03-31 0001851612 bhac:NotePayablePolarMember bhac:ProbabilityOfInitialBusinessCombinationMember 2025-03-31 0001851612 bhac:NotePayablePolarMember bhac:ProbabilityOfInitialBusinessCombinationMember 2024-12-31 0001851612 bhac:NotePayablePolarMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001851612 bhac:NotePayablePolarMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001851612 bhac:NotePayablePolarMember us-gaap:MeasurementInputExercisePriceMember 2025-03-31 0001851612 bhac:NotePayablePolarMember us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001851612 bhac:NonRedemptionAgreementsMember bhac:ProbabilityOfInitialBusinessCombinationMember 2025-03-31 0001851612 bhac:NonRedemptionAgreementsMember bhac:ProbabilityOfInitialBusinessCombinationMember 2024-12-31 0001851612 bhac:NonRedemptionAgreementsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001851612 bhac:NonRedemptionAgreementsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001851612 bhac:NonRedemptionAgreementsMember us-gaap:MeasurementInputExercisePriceMember 2025-03-31 0001851612 bhac:NonRedemptionAgreementsMember us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001851612 bhac:OperatingSegmentMember 2025-01-01 2025-03-31 0001851612 bhac:OperatingSegmentMember 2024-01-01 2024-03-31 0001851612 srt:MaximumMember us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001851612 us-gaap:SubsequentEventMember 2025-04-07 2025-04-07 0001851612 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2025-04-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares bhac:Business xbrli:pure bhac:Extension bhac:Warrant bhac:Director bhac:Vote bhac:Segment

Filing Compare · Focus Impact BH3 Acquisition Co